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Abstract  (English) 
Macrophages are resident immune cells that play a key role in host defense against 
pathogenic infections and in inflammatory responses and in physiological tissue 
remodelling. They are able to respond to a variety of microenvironmental stimuli, 
adopting different activation states depending on the activating signal and context, in 
order to eliminate the pathogen and restore homeostasis.  
Humans show strong sex differences in immunity to infection and autoimmunity, 
suggesting that sex hormones modulate immune responses. Indeed, estrogens regulate 
cells and pathways of the innate and adaptive immune systems, as well as immune cell 
development. Previous studies showed that 17β-estradiol (E2) is able to modulate the 
reactivity of macrophages during inflammation, down-regulating the expression of 
inflammatory genes. However, a full comprehension of the molecular details by which 
estrogens modulate macrophage activity is still unclear. To fill this gap we performed a 
transcriptomic analysis followed by biological assays of peritoneal macrophages 
isolated from female mice both with different endogenous estrogen levels and 
following short and long term estrogen administrations. 
The bioinformatic data suggested that E2 modulates important biological processes in 
macrophage physiology; among these, proliferation and the induction of an anti-
inflammatory and pro-resolution phenotype emerged as mostly significant. We thus 
confirmed this evidence by proving, through gene expression, FACS analyses and BrdU 
incorporation studies, that the proliferative index and macrophage cell number are 
induced by the estrogen surge. Furthermore, we demonstrated that hormone 
administration induces a dynamic activation process that evolves towards a pro-
resolving phenotype through the synthesis of IL10. Moreover, we observed that this 
activity is also maintained during peritoneal inflammation. 
By investigating the effects of E2 on microglia, a different macrophage population, my 
data highlighted the diversity in the E2 response of macrophages that reside in different 
tissues and the influence of the microenvironment on the hormone responsiveness and 
provided a list of E2 target genes that can be used as biomarkers for pharmacological 
and translational studies. 
Altogether, these results deepen our understanding of the endocrine-immune 
interactions and allow future studies on their relevance for the pathogenesis and 
development of therapeutic strategies of inflammatory pathological conditions. 
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Abstract  (Italian) 
I macrofagi sono cellule immunitarie che risiedono in quasi tutti i tessuti dell’organismo 
e svolgono un ruolo chiave nella difesa dell'organismo contro le infezioni dovute a 
patogeni e nelle risposte infiammatorie e un’importante funzione nel rimodellamento 
tissutale fisiologico. Essi sono in grado di rispondere ad una varietà di stimoli 
microambientali, adottando diversi stati di attivazione a seconda del contesto e del 
segnale di attivazione, con il fine di eliminare l’agente patogeno e ripristinare 
l’omeostasi. 
L’uomo mostra forti differenze legate al sesso nella risposta immunitaria alle infezioni e 
nell’autoimmunità, suggerendo che gli ormoni sessuali svolgono un importante ruolo 
nel modulare la risposta immunitaria. In effetti, gli estrogeni regolano diversi pathways 
del sistema immunitario innato e adattativo, nonché lo sviluppo delle cellule 
immunitarie. Studi precedenti hanno dimostrato che il 17β-estradiolo (E2) è in grado di 
modulare la reattività dei macrofagi durante l'infiammazione, down-regolando 
l'espressione di geni infiammatori. Tuttavia, non sono ancora del tutto chiari i dettagli 
molecolari attraverso cui gli estrogeni esercitano la loro attività anti-infiammatoria. Al 
fine di colmare questa lacuna, abbiamo effettuato un’analisi di trascrittomica, seguita da 
saggi biologici, dei macrofagi peritoneali isolati da topi femmina, sia in seguito a diversi 
livelli di estrogeni endogeni, sia in seguito a trattamento con estrogeni per breve e 
lungo termine. 
L’analisi dei dati bioinformatici ha mostrato che E2 modula importanti processi 
biologici coinvolti nella fisiologia dei macrofagi; tra questi emergono come più 
significativi la proliferazione e l'induzione di un fenotipo anti-infiammatorio e pro-
risolutivo. Abbiamo quindi confermato questi dati dimostrando, attraverso l'analisi di 
espressione genica, l’analisi citofluorimetrica e l’incorporazione di BrdU, che l'indice di 
proliferazione e il numero di macrofagi residenti aumentano in seguito ad un 
incremento dei livelli di estrogeno. Inoltre, abbiamo dimostrato che il trattamento con 
estrogeno induce nei macrofagi un processo di attivazione dinamico che evolve verso 
un fenotipo pro-risolutivo attraverso la sintesi di IL10. Inoltre questa azione 
dell’ormone sui macrofagi è mantenuta anche durante il corso di un’infiammazione 
peritoneale. 
Al fine di estendere le nostre osservazioni ad una diversa popolazione di macrofagi, 
abbiamo analizzato la risposta della microglia al trattamento con estrogeni mediante 
l'analisi di espressione genica. I risultati hanno evidenziato la diversità nella risposta a 
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E2 dei macrofagi che risiedono nei diversi tessuti e l’influenza del microambiente sulla 
reattività dei macrofagi a E2, inoltre, forniscono un elenco di geni bersagli 
dell’estrogeno che possono essere utilizzati come biomarcatori per studi farmacologici e 
traslazionali.  
Complessivamente, questi risultati approfondiscono la nostra conoscenza sulle 
interazioni del sistema endocrino-immunitario e permettono studi futuri sulla loro 
rilevanza nella patogenesi e lo sviluppo di strategie terapeutiche di condizioni 
patologiche infiammatorie. 
  
 
 
V 
 
   Index 
 
1. INTRODUCTION         pag 1 
1.1. Mechanisms of estrogen signaling       pag 2 
      1.1.1.  Estrogens          pag 3 
      1.1.2.  Estrogen synthesis        pag 4 
      1.1.3.   Structure and function of estrogen receptors    pag 6 
1.1.3.1  ERα and ERβ        pag 7 
 1.1.3.2  GPR30          pag 9 
      1.1.4  Mechanisms of estrogen action       pag 10 
 1.1.4.1  Direct genomic signaling       pag 10 
 1.1.4.2  Indirect genomic signaling      pag 11 
 1.1.4.3  Ligand independent signaling      pag 12 
 1.1.4.4  Non genomic signaling      pag 14 
1.2 Macrophages          pag 15 
         1.2.1  Macrophage origin and functions       pag 16 
         1.2.2  Tissue resident macrophage populations      pag 18 
1.2.2.1 Peritoneal macrophages       pag 21 
1.2.2.2 Microglia         pag 24 
         1.2.3  Macrophage self-renewal        pag 25 
1.2.3.1 Macrophage proliferation induced by CSF1    pag 26 
1.2.3.2 Macrophage proliferation induced by IL-4    pag 27 
         1.2.4 Macrophage activation        pag 29 
1.2.4.1 M1 Macrophage polarization      pag 30 
1.2.4.2 M2 Macrophage polarization      pag 31 
1.3 Estrogen action on macrophages in physiology       pag 34 
      1.3.1 Estrogen as inflammatory regulator       pag 36 
      1.3.2 Effect of estrogen on macrophages        pag 38 
1.3.2.1 Estrogen action on M2 macrophage activation      pag 40 
1.3.2.2 Macrophage ERαKO           pag 41 
1.4 Relevance of estrogen action on macrophages in pathology    pag 42 
 
 
VI 
 
           1.4.1 Endometriosis          pag 43 
           1.4.2 Cancer            pag 44 
           1.4.2 Neurodegenerative diseases        pag 46 
2. AIM OF THE STUDY           pag 47 
3. METHODS           pag 49 
     3.1. Animal models and treatments        pag 50 
           3.1.1. Zymosan peritonitis model        pag 51 
           3.1.2 BrdU injection          pag 51 
           3.1.3 Intracerebroventricular injection of IL-4      pag 51 
     3.2 Peritoneal and bone-marrow-derived macrophages (BMDMs)   pag 52 
     3.3 Microglia isolation          pag 53 
     3.4. Flow cytometry analysis           pag 54 
     3.5 RNA preparation and analysis            pag 55 
     3.6 Bioinformatics analysis         pag 56 
     3.7 Statistical analysis          pag 57 
4. RESULTS           pag 58 
     4.1. Bioinformatic analysis of macrophage genes modulated by estrogens  pag 61 
           4.1.1. Differentially expressed genes (DEGs) in macrophages following    pag 61              
E2 treatment           
           4.1.2 Bioinformatic transcriptional analysis of DEGs     pag 63 
           4.1.3 Biological pathways regulated by 17-βestradiol in resident        pag 65                          
macrophages            
     4.2 Estrogen is a physiological trigger of peritoneal macrophage cell cycle  pag 67 
           4.2.1 Cell cycle genes         pag 67 
           4.2.2 Macrophage proliferation        pag 68 
           4.2.3 Ovariectomy affects macrophage population     pag 70 
     4.3 Estrogen is a physiological trigger of M2 peritoneal macrophage          pag 72      
polarization 
           4.3.1 M2 macrophage polarization genes      pag 72 
           4.3.2 Macrophage phenotypic adaptation following E2 action   pag 73 
           4.3.3 Estrogen promotes macrophage alternative polarization       pag 75                             
in an in vivo model of self-resolving inflammation 
 
 
VII 
 
    4.4 Molecular mechanism of estrogen action on macrophages    pag 78 
     4.4 Microglia response to the estrogen surge      pag 80 
           4.4.1 Microglia and macrophage response to IL-4  pag 82 
5. DISCUSSION          pag 84 
6. ACKNOWLEDGMENTS         pag 90 
7. BIBLIOGRAPHY          pag 92 
8. SUPPLEMENTARY MATERIALS        pag 115
 
 
INTRODUCTION 
  
 
 
2 
 
1.1 Mechanisms of estrogen signaling 
Estrogens are steroid hormones initially isolated and characterized in the late 1920ies by 
Adolf Butenandt (Nobel laureate for this discovery) and Edward A. Doisy [1]. They are 
present in all vertebrates and some invertebrates and are traditionally considered as the 
primary female sex hormones since they are produced by the ovary, released into the 
blood and play a key role in the control of female reproduction.  In fact, estrogens most 
important role in women is to develop the secondary sexual characters of woman and 
establish and maintain reproductive functions, controlling uterine and mammary 
growth and function.  
But, in addition to the effects on female reproductive functions, estrogens play 
important role in the regulation of skeletal homeostasis, lipid and carbohydrate 
metabolism, skin physiology, cardiovascular system, liver, central nervous system, 
immune system and tissue remodelling [2-6]. These effects are also due, at least in part, 
to extragonadal synthesis of estrogens; for this reason estrogens exert important 
functions not only in female but also in male physiology. Moreover, estrogens are been 
demonstrated to be crucial for early development, not only for primary and secondary 
sexual characteristics but also embryonal and fetal development of  brain networks [7]. 
Estrogens action is mediated by the binding to their receptors; in spite of the 
importance and the wide role of estrogen signaling, there are only three known 
estrogen receptors (ER) that mediate hormone action: ERα, ERβ and G protein-coupled 
estrogen receptor 1 (GPER1 or GPR30). The complexity of estrogen action is further 
enlarged by the different mechanisms of hormone signaling, that is direct and indirect 
genomic signaling, ligand independent signaling and non genomic actions [8,9]. 
Considering the relevance of estrogen action on extragonadal tissues, that show both 
tissue- and cell-specific estrogen synthesis and signaling, estrogen treatments are 
currently under evaluation in clinical trials for several aging-related diseases. 
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1.1.1 Estrogens  
They are three main forms of physiological estrogens in females: estrone (E1), estradiol 
(E2 or 17β-estradiol) and estriol (E3) (Figure 1). Each of these forms represents different 
product that derives from cholesterol through a sequence of reactions of estrogen 
biosynthesis. 
Estrone is the major estrogen in postmenopausal women; it is produced primarily in 
adipose tissue from adrenal dehydroepiandrosterone (DHEA), although little amounts 
are synthesized in ovaries and adrenal glands. Estrone is provided with mild estrogenic 
capacity compared to estradiol, as it weakly interacts with estrogen receptors. Estradiol 
is the major estrogen form present in premenopausal women; it is synthesized in 
ovaries, by placenta during pregnancy, and also in adrenal glands and through 
testosterone peripheral conversion at little amounts. Estradiol secretion into the 
circulation is regulated by pituitary gonadotropins, follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH), and is characterized by  a specific cyclical trend during 
menstrual cycle. Lastly, estriol plays an important role during pregnancy when it is 
produced in large quantities by the placenta and generated from E1 through 16α-
hydroxylation. 
  
 
 
  
 
 
 
 
 
 
 
 
Figure 1. Chemical structure of physiological estrogens. 
Chemical structure of A) estrone (E1) B) estradiol (E2) and C) estriol (E3)  
 
 
 
 
 
 
Estrone Estradiol Estriol 
A B C 
 
 
4 
 
1.1.2 Estrogen synthesis  
The synthesis of estrogen is different between reproductive and non reproductive 
women.  
In reproductive women, ovaries are the main source of circulating estrogens, although 
during pregnancy, also placenta is able to produce significant amounts of hormone 
which is secreted into the circulation [2]. 
In the ovaries, the biosynthesis of estrogen is finely regulated by two hormones released 
from the pituitary gland, namely FSH and LH, which production is positively 
influenced by hypothalamic neurohormone, such as gonadotropin-releasing hormone 
(GnRH), and involved different cell types (Figure 2). In particular, thecal cells can 
produce androgens from progesterone but are unable to convert androgens into E2. On 
the other hand, granulose cells are not able to produce androgens from progesterone, 
but can synthesize E2 from androgens through the action of aromatase enzyme [10]. 
Thus, during folliculogenesis, thecal cells produce androgens following LH interaction 
with specific receptors.  Then, following FSH stimulation, androgens are released, 
transported in granulose cells and converted in E2; this latter is then released into the 
bloodstream to act on estrogen-responsive tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cell-specific estrogen synthesis in the ovary during folliculogenesis. Figure taken from Cui et al., 2013 
[11]. Estrogens synthesis starts with the production of pregnenolone from cholesterol, through the action of 
cytochrome P450 side chain cleavage enzyme (P450scc). Pregnenolone is then converted to progesterone by 3-beta-
hydroxysteroid dehydrogenase (3β-HSD) in both thecal and granulose cells. Progesterone is converted to androgens 
by cytochrome P450 17α-hydroxylase (P45017α) and 17-beta-hydroxysteroid dehydrogenase (17β-HSD) in thecal 
cells during the follicular phase. The conversion of E2 is catalyzed by aromatase (P450Arom) in granulosa cells.  
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In nonreproductive women, instead, the main source of estrogens is represented by 
their synthesis in extragonadal tissues, such as breast, kidney, adipose tissue, skin and 
brain [12], and depend on the availability of C19 steroid  precursors, that is testosterone, 
androstenedione, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone 
sulfate (DHEAS). The enzymatic reactions that lead to the production of estrogens from 
C19 steroid precursors are schematized in Figure 3. 
In contrast to ovaries, estrogen produced in extragonadal sites is not released into the 
circulation, but acts locally as autocrine, paracrine or intracrine factor to control tissue 
homeostasis and functions [13]. 
Also men widely depend on local synthesis of E2 in extragonadal sites; but it is also 
produced in male testes where control gonadal development and functions and 
regulate spermatogenesis [14]. 
 
 
 
Figure 3. Schematic representation of enzymatic reactions of 
estrogen synthesis in extragonadal tissues. Figure taken from 
Vrtačnik et al., 2014 [15] 
Estrogens are synthesized from C19 steroid precursors through 
several enzymatic steps. 
3β-hydroxysteroid dehydrogenase (3β-HSD); 17β- hydroxysteroid 
dehydrogenase (17β-HSD); dehydroepiandrosterone (DHEA); 
dehydroepiandrosterone sulfate (DHEAS); 5α-dihydrotestosterone 
(DHT). 
 
 
 
 
 
Levels of circulating E2 depend on reproductive status - reaching highest level during 
reproductive years and declining during postmenopausal period - and menstrual cycle, 
reaching the highest plasma concentration immediately before ovulation [16].  The main 
differences in estrogen synthesis as well as plasma E2 levels based on reproductive 
status and sex are summarized in Table 1. 
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Premenopausal       
women 
       Postmenopausal         
women 
        Men 
Source of circulating 17β-
estradiol 
ovaries (around 95%)                      
adrenal cortex        
(around 5%) 
extragonadal tissues 
(around 100%) 
extragonadal tissues 
(around 100%) 
Plasma levels of 17β-
estradiol 
0.11-2.20nM                                 
(depending on the phase 
of the cycle) 
around 0.04 nM around 0.10 nM 
Source molecules for 17β-
estradiol synthesis 
blood-derived cholesterol 
and acetyl coenzyme A 
testosterone, 
adronstenedione, DHEA 
and DHEAS 
testosterone, 
adronstenedione, DHEA 
and DHEAS 
 
Table 1 Differences in estrogen synthesis based on sex and menopause. Modified from Vrtačnik et al., 2014 [15]. 
 
Deactivation and circulating levels of E2 are regulated by different mechanisms that 
involved estrogen metabolism, such as the conversion of E2 in less active forms (E1 or 
E3) [17] and, most of all, regulation of aromatase enzyme. Aromatase, a member of 
cytochrome P450 superfamily, catalyzes the last step of E2 synthesis and is broadly 
expressed in several tissues, such as gonads, liver, brain, adipose tissue and 
endometrium [18]. It is characterized by tissue-specific expression due to three main 
factors: alternative splicing, tissue-specific promoters and different transcription factors 
[19-21]. Moreover aromatase activity is also regulated by post-translational 
modifications such as phosphorylation [22]. 
 
1.1.3 Structure and function of estrogen receptors 
Estrogen exerts their biological effects by binding their designated receptors (ERs), that 
are ERα, ERβ and GPR30 . 
ERα and ERβ are members of nuclear receptors superfamily and act as ligand-activated 
transcription factors, modulating the transcription of specific genes that have an 
estrogen-responsive element (ERE) in their promoter. GPR30, instead, is a membrane 
receptor. While biological effects mediated by nuclear ERs take hours to days to 
develop, cell membrane ERs mediated a rapid intracellular response that takes seconds. 
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1.1.3.1 ERα and ERβ 
These receptors are characterized by high sequence homology which it is reflected in a 
strong structural homology. ERα was the first estrogen receptor described, identified in 
1986 by Chambon’s laboratory [23]. After, a second ER, named  ERβ, was identified in 
1996 [24]. ERα and ERβ are not isoforms but different receptors encoded by two distinct 
genes located on different chromosomes, ESR1 on chromosome 6 (10 in mouse) and 
ESR2 on chromosome 14 (12 in mouse) respectively [25-29]. 
ERα and ERβ are expressed in several cell types, although each receptor has a tissue-
specific distribution in the body. ERα is the receptor predominantly expressed in 
uterus, ovary, testes, breast, bone, liver, kidney, heart, pituitary gland and adipose 
tissue. ERβ is mainly expressed in ovary (granulose cells), prostate (epithelium), colon, 
vascular endothelium, lung and bladder [30]. In the brain, both receptors are broadly 
expressed by both neurons and glial cells.  
 
 
 
 
 
Figure 4. ERα and ERβ distribution throughout 
the body. Figure taken from Drummond and 
Fuller, 2010 [31]. 
 
 
 
Tissue distribution of ER correlates with their functions. In fact, ERα is mainly involved 
in the regulation of neuroendocrine and reproductive systems, instead, ERβ have an 
important role in the regulation of cognitive functions [30,32-33]. 
Nuclear ERs consist of five functional domains (Figure 5): A/B or N-terminal domain 
(NTD), C or DNA binding domain (DBD), D or hinge region, E region or Ligand 
binding domain (LBD) and F or C-terminal domain [34-38]. 
A/B or N-terminal domain (NTD). This region is the least conserved among the 
different members of the family of intracellular receptors. It contains Activation 
Function-1 (AF-1) domain, that is able to exercise its action in a ligand independent 
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way. The activation mediated by AF1 is very weak, but it synergizes with the AF2 
domain present in region E [39]. Post-translational modifications, such as 
phosphorylation, of the A/B domain can dramatically affect the overall behavior of the 
receptor and represent a mechanism for the modulation of AF-1 functions [40]. 
C region or DNA binding domain (DBD).  This is a highly conserved region involved 
in DNA binding. It is characterized by the presence of basic amino acids that facilitate 
the interaction with the phosphate groups of the DNA and contains two zinc fingers, 
each composed of four cysteine residues that chelate a single Zn2+ ion. These two 
domains recognize and bind specific DNA sequences, known generically as Hormone 
Responsive Elements (HREs) which in the specific case of the estrogen receptor are 
called EREs (Estrogen Responsive Elements). Further feature of the C region is the 
presence of the Proximal Box (P-box) consisting of three amino acids that confer DNA 
sequence recognition specificity to the receptor for HRE sequences and Distal Box (D-
box) involved in receptor dimerization. 
D or Hinge region. Flexible Region that links C domain to E and binds Hsp90 
chaperone appointed to maintain the receptor in a metastable conformation capable of 
binding to the ligand. Moreover, this region contains a nuclear localization signal, it is 
involved in ER cellular compartmentalization and it is a site of post-translation 
modifications [41]. 
E region or Ligand binding domain (LBD). This domain has important role in ligand 
binding, receptor dimerization and in the binding with coactivators and co-repressors. 
Moreover, this region contains AF2 domain involved in the hormone-dependent 
transcriptional activity.  
LBD consists of 11 alpha-helices (H1 and H3-H12) and 2 β-sheets that form a 
hydrophobic ligand-binding pocket closed to the C-terminal region [42]. 
Following receptor binding to an agonist, LBD changes its conformation, in particular, 
H12 helix rotates and forms a hydrophobic pocket leading to the exposure of a surface 
consisting of helixes 3, 4, 5 and 12 that allows coactivators recruitment and activation of 
the transcription. Conversely, estrogen antagonists are unable to induce a similar 
repositioning of H12, preventing coactivators  recruitment and the activation of 
transcription. 
F or C-terminal domain. It is a little conserved region with few known functions. Some 
data indicate its involvement in coactivators recruitment and receptor dimerization and 
stability [43-47]. 
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Figure 5. Structures of ERα and ERβ protein with functional domains. Figure taken from Hewitt et al. 2016 [48]. 
Structures of ERα and ERβ protein with functional domains. Estrogen receptors ERα and ERβ share a conserved 
domain structure. The A/B domain, at the amino terminus (N) of the protein contains AF-1. The C domain binds to 
DNA motifs called EREs. The D domain is called the hinge region, and contributes to DNA binding specificity and 
nuclear localization of the ERs. The E domain is called the ligand binding domain because it interacts with estrogen, 
through an arrangement of 11 α helices (H1, and H3 through H12). H12 in this region of the receptor is critical to 
mediating transcriptional activation via AF-2. At the carboxy terminus (C) is the F domain. The % homology shared 
between ERα and ERβ in the C and E domains is shown. 
 
ERα and ERβ show high structural homology; both are formed from a single 
polypeptide chain consists of 599 aa for ERα and 549 aa for ERβ. However, sequence 
homology varies in the different domains and the less conserved regions appear to be 
those involved in transcription regulation. In fact, DBD and LBD have a homology of 
95% and 60%, respectively, instead A/B and F regions have a homology of only 16% and 
18%. This difference leads to hypothesize that the two receptors show a degree of 
specificity for the promoters of target genes. 
Moreover, the two receptors differs also in dimerization process: while ERα acts 
preferentially in the homodimer form, the main active form for ERβ is the heterodimer 
with ERα and some evidence suggests that ERβ can exert an inhibitory effect [49]. 
 
1.1.3.2 GPER30 
GPR30 is an orphan G protein coupled receptor, discovered by different independent 
groups as membrane estrogen receptor triggering rapid estrogen non-genomic 
signaling independent of ERα and ERβ [50]. Some data showed that higher 
concentration of E2 was needed to activate this receptor, due to the lower ligand affinity 
for this receptor compared to ERα and ERβ. GPR30 is expressed in ovaries, adrenal 
medulla, renal pelvis, and different brain regions [51, 52]. However, there are few 
studies about this receptor and conflicting information about its localization. 
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1.1.4 Mechanisms of estrogen action 
Estrogens are able to mediate their function through their interaction with their 
receptors. Estrogen signaling can be divided into two main activation pathway: 
genomic and non-genomic signaling [53]. Genomic signaling can be divided into three 
pathways: direct genomic signaling, indirect genomic signaling and ligand-
independent signaling. 
 
1.1.4.1 Direct genomic signaling 
This pathway is considered as the classical mechanism of estrogen signaling.  
In the absence of ligand, the receptor is sequestered in the cytoplasm of the target cells, 
complexed with Heat shock proteins (Hsp)70, Hsp90 and Hsp56, whose function is to 
maintain the receptor in a conformation with high affinity for the hormone and to mask 
the nuclear localization sequence and the DNA binding domain [54]. 
The estrogen binding to the lipophilic cavity of the domain E of ERα or ERβ in the 
cytoplasm of target cells determine structural changes involving the reposition of helix-
12 and the release of the Hsps that allow receptor dimerization (with homo or hetero 
dimers formation), translocation into the nucleus and the interaction with EREs located 
in the promoters of target genes. 
The receptor-DNA binding in correspondence of ERE sites leads to a series of 
interactions with nuclear proteins, including co-regulators, and transcription factors, 
which allow the receptor-ligand complex to regulate the transcription of target genes; 
the link with co-activators facilitates, while the one with the corepressor inhibits the 
binding of the initiation transcription complex on the promoter of the target genes. 
The co-activators such as p160 and P/CAF, and the proteins recruited, as CBP/p300, 
facilitate recruitment of the RNA polymerase II transcriptional machinery and the 
synthesis of the primary transcript. The co-repressors, instead, are proteins able to 
repress the transcriptional activity of nuclear receptors by binding to their LBD. Among 
the main co-repressors, the better characterized  are NCoR (Nuclear Co-Repressor) and 
SMRT (Silencing Mediator of Retinoid and Thyroid hormone receptors).  
The modulated  response is observed after a few hours, usually, by the interaction of 
estrogen with the receptor. 
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In this way, estrogen-ER complex acts as a transcriptional activator promoting gene 
expression and the response is usually observed after a few hours by the interaction of 
estrogen with the receptor [55]. 
 
 
 
 
Figure 6. Direct genomic signaling. This pathway promotes 
target genes expression by binding the E2-ER complex 
directly to the ERE [56]. 
 
 
 
 
 
 
 
1.1.4.2 Indirect genomic signaling 
17β-estradiol can also modulate the expression of genes that have not EREs in their 
promoters. In fact, around one third of the estrogen responsive genes lack ERE-like 
sequences, for example, IL-6, TNF-α and MPC-1 genes don’ t have ERE sequences in 
their  promoters, but their transcription is inhibited by estrogen.  
In the case of ERE-independent genomic signaling, ERs don’t have a direct 
transcriptional effect, but its action is mediated by their  binding with other classes of 
transcription factors at their respective response elements. This mode of action enables 
activation or repression of target genes expression. One of the best described examples 
includes interaction of estrogen-ER complex with FBJ murine osteosarcoma viral 
oncogene homolog (FOS) and jun proto-oncogene (JUN) proteins at the activator 
protein 1 (AP-1) binding sites in genes encoding  insulin-like growth factor 1 (IGF1), 
collagenase, cyclin D1 (CCND1) and choline acetyltransferase [56-61]. The result 
depends on the ER subtype and type of the ligand. 
Other transcription factors that facilitate estrogen signaling also include Sp1 
transcription factor, nuclear factor kB (NFkB), CCAAT/enhancer binding protein β 
Nucleus 
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(C/EBPβ) GATA binding protein 1 (GATA1) and signal transducer and activator of 
transcription 5 (STAT5) [56]. 
 
 
 
 
 
Figure 7. Indirect genomic 
signaling. E2- activated ERs bind 
DNA trough protein-protein 
interactions with other classes of 
transcription factors at their 
respective response elements. [56]. 
 
 
1.1.4.3 Ligand independent signaling 
ERs can be activated in the absence of the  ligand. In fact, in the presence of particular 
extracellular signals, activated molecules are able to favor post-transcriptional 
modification, such as phosphorylation or acetylation, or phosphorylation of ERs 
associated coregulators allowing ligand-independent ER activation. These 
modifications are  carried out by enzymes associated with membrane receptors, such as 
MAPK and JAK, and, when activated, generate a cascade of intracellular signals capable 
to regulate receptor activation. 
Peptide growth factors, such as epidermal growth factor (EGF), insulin, IGF1 and 
transforming growth factor β (TGFβ), protein kinase A (PKA) or protein kinase C 
(PKC), neurotransmitters and cyclins are important group of estrogen-independent ER 
activators phosphorylating the receptor [62]. In fact, N terminal portion of ERs contains 
several serine residues that are target of phosphorylation. For example, 
phosphorylation of Ser 118 of ER is induced by EGF  and depends on the activation of 
MAPK [63]. 
 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
 
 
Figure 8. Ligand-independent signaling. This 
pathway causes ER activation and target gene 
transcription through phosphorylation of ERs on 
their associated coregulators . [56]. 
 
 
Classic genomic mechanism represents only a small part of to the complexity of 
estrogen signaling. Estrogen is able to modulate the expression of the same target gene 
through multiple mechanisms, both genomic and non-genomic. Moreover, the same 
promoter sequence can harbor both ERE as well as response elements associated with 
other transcription factors. The final result therefore depends on multiple factors 
including combination of transcription factors present on the gene promoter, expression 
levels and cellular localization of all three ERs, their various coregulators, and signaling 
components, as well as the nature of the stimuli. Since these variables can differ 
significantly among various cell types, it is possible that estrogens use distinct signaling 
pathways depending on the cellular context and in this way ensure very precise and 
cell-specific regulation of target gene expression. 
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1.1.4.4 Non genomic signaling 
Estrogens are also able to modulate rapid  biological effects (within seconds or 
minutes). Non-genomic estrogen signaling is mediated by a subset of membrane ER, 
e.g. GPR30 and  variants of ERα and ERβ. Binding of estrogens to ERs located at the cell 
surface can cause mobilization of intracellular calcium, stimulation of adenylate cyclase 
activity and modulation of the cytoplasmic contents of cyclic adenosine 
monophosphate (cAMP), activation of the mitogen-activated protein kinase (MAPK) 
signaling pathway, modulation of the phosphoinositol 3-kinase (PI3K) signaling 
pathway and activation of membrane tyrosine kinase receptors [64-65].  
For example, estrogen activates endothelial nitric oxide synthase (eNos), through 
MAPK and PI3K/Akt pathway [67-68]. In osteoblasts and osteoclasts, E2 rapidly 
activates the MAPK signaling involved in the proliferation and apoptosis of these cells, 
modulating bone homeostasis [69]. 
GPR30 instead is specifically associated with the stimulation of adenylate cyclase and 
activation of EGFR [66]. Molecular mechanisms underlying non-genomic estrogen 
signaling are different and numerous and may depend on a number of conditions, such 
as the availability of signal transduction molecules and downstream targets, suggesting 
a cell type-specific mechanism. 
 
 
 
 
Figure 9. Non-genomic signaling. This 
pathway starts with the binding of E2 to the 
ERs located at the plasma membrane 
resulting in the activation of various protein-
kinase cascades. [55]. 
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1.2 Macrophages 
Macrophages were originally identified in the late 19th century by Elie Metchnikoff 
[70], that described their phagocytic activity (Nobel Prize in Physiology or Medicine for 
the discovery of phagocytosis) [71]. 
Macrophages are a heterogeneous population of immune cells that populate all tissues 
and play key role in tissue integrity and  homeostasis; they show a high phagocytic 
activity and are able to recognize and respond to tissue damage and infection [72-73]. 
Tissue macrophages show a strong anatomical and functional diversity as well as 
transcriptional difference recently revealed by a global transcriptome analysis of 
purified tissue macrophage populations by the Immunological Genome Project, 
highlighting their specialized role in different tissues. 
In 1968 van Furth and Cohn showed that major populations of tissue macrophages 
were originated from blood monocytes [74] and classified macrophages as mononuclear 
phagocytic system (MPS); in this proposed model macrophages derived from blood 
monocytes developed from bone marrow precursors. This idea remained viable for over 
40 years, although there was already evidence that the tissue macrophages were 
independent from circulating monocytes [74-76]. However, some recent evidence 
demonstrated that this definition is inadequate as macrophages have several origins 
during ontogeny and  each of these different lineages persist into adulthood [77]. 
Functional classification of macrophages, instead, is based on inflammatory states and   
according to this criteria itis possible to group these cells into two main classes: the ‘M1-
M2 paradigm’. 
Thus, macrophages are heterogeneous population of cells that constantly shift their 
phenotype in response to changes in environmental challenges and stimuli and they 
should be considered as different subtypes of cells according to their different origins. 
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1.2.1 Macrophage origin and functions 
Evidence indicates that exist at least three lineages of macrophages that originate at 
different stages of development and persist in the adulthood. 
The first lineage is based on MPS model and involves a series of progenitors in 
temporal succession. Primitive progenitors of macrophages originate from early and 
late erythro-myeloid progenitors (EMPs) generated in yolk sac from primitive ectoderm 
during primitive hematopoiesis at embryonic day 8. These EMPs can arise macrophages 
that not have a monocytic precursors. Subsequently, this primitive system is followed 
by definitive hematopoiesis in the fetal liver. Fetal liver monocytes are generated from 
EMPs derived from yolk sac or from hematopoietic stem cells (HSC) originated from 
hematogenic endothelium of the aortogonadal-mesonephros region of the embryo; 
these progenitors migrate to the fetal liver in two successive waves E9.5 (EMPs) and 
E10.5/E11 (HSCs) and generate circulating monocytes during embryogenesis. Following 
postnatal bone formation, hematopoiesis in the liver declines and starts in the bone 
marrow. Bone marrow hematopoiesis represent the source of circulating monocytes 
(resident, lymphocyte antigen 6c negative (Ly6c2) and inflammatory (Ly6c1) and from 
which some resident macrophages derived. 
Second lineage of macrophages derives from yolk sac progenitors. Tissue resident 
populations of macrophages (F4/80 high) in skin, spleen, pancreas, liver, brain and lung 
originate from yolk sac progenitors, as demonstrating by studies using ablation of c-
Myb-dependent bone marrow hematopoiesis and next transplantation with different 
bone marrow [78]. 
The third lineage arises from fetal liver;  as occur for Langerhans cells that have a mixed 
origin from yolk sac and fetal liver [79]. 
The master regulator of macrophage lineage is macrophage colony-stimulating factor 1 
receptor (CSF1R), a transmembrane tyrosine kinase receptor [80]. CSF1R is involved in 
differentiation of macrophages and its ablation lead to a severe depletion of 
macrophages in several tissues, such as brain, ovaries, bone and skin [81]. 
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Figure 10. Macrophage lineages in mice Modified from Wynn et al., 2013 [73]  
The mononuclear phagocytic system in adults derives from at least three sources. The first is the yolk sac, which 
produces progenitors that populate all tissues and that have progeny that persist throughout life as F4/80 bright 
resident macrophages. These lineages are mainly regulated by CSF1R and its ligands, IL- 34 and CSF1. The second is 
the fetal liver, and this is less well defined but seems to contribute to the production of adult Langerhans cells, 
perhaps through a progenitor that is derived from the yolk sac. The third lineage derives from the bone marrow (BM) 
to give circulating monocytes and their progeny F4/80low macrophages, and dendritic cells (DCs). In this case the 
Ly6c1 monocytes give rise to the classic Steinman dendritic cells under the regulation of FLT3, and these are 
continuously replenished. Other macrophages that are F4/80low also emanate from Ly6c1 monocytes, and in some 
cases—such as in kidney and lung—they co-exist with those derived from the yolk sac to give chimaeric organs. The 
exact role of the patrolling Ly6c– macrophages, and the contribution of fetal liver to adult tissue macrophages, 
remain unclear. CDP, committed dendritic cell progenitor; MDP, monocyte dendritic cell progenitor 
 
 
Despite the diversity of tissue resident macrophages, they show some common 
functions  such as phagocytosis and the secretion of  pro- and anti- inflammatory 
cytokines with autocrine and paracrine functions. [82].  
Macrophages play important role in several features of organism’s biology; from 
development,  homeostatic functions, such as iron processing ant clearance of 
lipoproteins, debris and dead cells, regulation of tissue metabolism, remodelling and 
repair [83-85], to immune response to pathogens, that involved immune surveillance, 
response to infection and the resolution of inflammation.  
These cells participate in both the innate immune response, representing the  first line 
defense of  organism against external insults, and secondary or specific response; their 
primary function is to recognize and engulf pathogens, toxic substances and cellular 
debris, through pattern recognition, scavenger and phagocytic receptors [86-89]. 
The main functions of macrophages can be summarized in the following ones: 
Large peritoneal 
macrophages 
Small peritoneal macrophages 
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 phagocytosis, an important processes for  the turnover of old or damaged cells 
(for example, erythrocytes), and especially for the immune response, since they 
are able to recognize, incorporate, and delete toxic elements; 
 secretion, macrophages are able to produce and secrete several biologically 
active molecules such as cytokines (interleukins: IL-1, IL-12, INF-α, TNF), 
chemokines and proteolytic enzymes (such as plasminogen activators, elastase, 
collagenase). 
 antigen presentation to CD4+ T lymphocytes, macrophages are professional 
Antigen-Presenting- Cells (APC): they are specialized in antigen capture, 
processing and presentation by MHC Class II to other cells of the immune 
system. 
 
1.2.2 Tissue resident macrophage populations 
Macrophages populate the majority of tissues in the body and phenotypically distinct 
subsets of macrophages are often present in tissue microanatomical niches. Resident 
macrophages regulate tissue homeostasis acting as sentinels and responding to any 
changes in tissue environment.   
Macrophages show specific phenotypic characteristics and express particular markers. 
For example, in mice, macrophages express the hematopoietic lineage marker CD45 but 
not markers of other immune cells, such as CD3 and CD20. They express the receptor 
for macrophage colony-stimulating factor (M-CSF or Csf1), the integrin CD11b, and two 
important scavengers of foreign antigens and apoptotic cells: Fcg receptor 1 (FcgRI) 
CD64 and the receptor tyrosine kinase MerTK [86].  
However, it was observed a marked difference in gene expression profile of resident 
macrophages in the  different tissues, suggesting a distinct transcriptional program for 
each population. For example, only spleen resident macrophages express Spi-C gene, 
essential in the recycling of iron from old red blood cells, or Gata6 is selectively 
expressed by peritoneal macrophages [90]. This transcriptional difference leads to a 
strong diversity and specialized functions of macrophages resident in the different 
tissues, that are summarized in Table 2. For example, in steady state condition, 
microglia regulates neuronal plasticity, alveolar macrophages, instead, engulf 
surfactant proteins preventing proteinase condition [92-93]. This diversity is regulated 
by different master controls in a tissue and niche-specific manner (Figure 11).  
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Table 2. Distinct locations and functions of tissue macrophages. Table from Davies et al., 2013 [91]. 
aThis table represents a simplification and marked heterogeneity is evident in many tissues (for example, bone 
marrow, peritoneum, lung and liver) highlighted through fate mapping studies and phenotypic variation. 
bOrigin indicated only where experimentally established. 
cSelect examples of tissue selective transcriptional regulators involved in cellular development or function are 
indicated. 
dMarker is expressed by the majority of the indicated cells. Subsets are only listed where distinct anatomical 
localization, function or origins are reported, and not those that are simply defined by variation in select 
receptor/antigen expression. 
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Surrounding microenvironment itself is crucial to modulate macrophage functions and 
phenotype, providing tissue-specific signals influencing the expression of several genes 
regardless of origin and orchestrating the differentiation [94]. In fact, tissue local 
production of cytokine and substances are involved in the regulation, maintenance and 
functional specialization of macrophages: Csf1 is important for survival and 
proliferation of macrophages in several tissues, instead, IL-34 (whose signaling is 
mediated by Csf1r), Csf2 (or GM-CSF) and oxysterols regulate macrophage functions in 
specific tissues (Figure 11), although the  role of these cytokines must to be better 
investigated in vivo [95]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Tissue microenvironment determines macrophage differentiation. Taken from Lavin et al., 2015 [96]  
Macrophages in all tissues are characterized by expression of the cell surface marker, such as  FcγRI (also known as 
CD64), tyrosine-protein kinase MER (MERTK) and the transcription factors PU.1. In the tissues, macrophage identity 
and functions are shaped by cytokines and metabolites that are produced in the local environment and drive specific 
transcription factor expression.  
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1.2.2.1 Peritoneal macrophages 
The peritoneal cavity (PerC) is a single fund, in which coexist a variety of immune cells, 
such as eosinophils, neutrophils, B cells, dendritic cells and macrophages. 
Peritoneal macrophages are the best studied population of macrophages. In fact, most 
of the current information about macrophage biology, function, specialization and 
development come from studies performed using peritoneal macrophages as a cell 
source. However, only recently it has been demonstrated the presence of two different 
subpopulations of resident macrophages in PerC that are functionally and 
phenotypically heterogeneous [97]. 
On the basis of their size, these subpopulations are defined as Large Peritoneal 
Macrophages (LPMs), that constitute the most abundant population of macrophages 
present in the peritoneal cavity, about 90%, and Small Peritoneal Macrophages (SPMs). 
Both subpopulations show phagocytic activity in vivo and express macrophage typical 
surface markers, such as F4/80 and CD11b, although they show different expression 
levels of these markers. In fact, LPMs express higher levels of F4/80 and CD11b while 
SPMs show F4/80lowCD11blow phenotype (Table 3). Analysis of microscopy and flow 
cytometry demonstrated that SPMs and LPMs are characterized by different 
morphology and phenotype. Indeed LPMs display classical morphology with 
prominent vacuolization and abundant cytoplasm, whereas SPMs have a polarized 
morphology with dendrites similar to DCs [99]. Moreover, the analysis of a complex 
panel of cell surface molecules  demonstrated that they differ in the expression of a 
wide variety of other surface molecules (Table 3), such as Gr-1 and MHC-II, and several 
studies demonstrated different response patterns following treatment with classical 
macrophage stimuli (such as lipopolysaccharide). 
This difference in quantitative expression of a series of surface molecule between the 
two subtypes of peritoneal macrophages or the lack of expression by SPMs or LPMs of 
some surface markers allows to distinguish these two populations in qualitative ways. 
In fact, LPMs express Gr-1 and AA4.1 while SPM not. In contrast, SPMs express MHC-II 
while LPMs express very low levels of this marker (Table 3). 
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Table 3. Different expression profile of surface markers between SPMs and LPMs. Taken from Cassado  et al., 2013 
[98]. 
 
LPMs and SPMs are also functionally distinct; although both populations show 
phagocytic activity in vivo, SPMs seem to be characterized by a more efficient 
phagocytosis. Furthermore, it has been demonstrated that LPMs produce more NO in 
response to LPS in vitro compared to SPMs, although in vivo were obtained quite 
different results [97]. 
The two populations differ also for the origin and development (Figure 12): in 
homeostatic conditions LPMs derive from proliferation in situ regardless hematopoiesis, 
SPMs, instead, are produced from circulating monocytes. Factors arising from the 
microenvironment play an essential role in promoting phenotypic development of 
peritoneal macrophages, an example of this mechanism is represented by RA-derived 
factor that promotes the omentum expression of GATA-6 transcription factor selectively 
expressed by LPMs, determining their location and function. Instead, the factors that 
regulate the SPMs pool in the steady state are still unclear. 
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Figure 12. Origin of peritoneal macrophages. Taken from Cassado et al., 2015 [98]  
SPMs are produced by the cell hematopoietic stem cell (HSC) in bone marrow (BM) for differentiation  of circulating  
inflammatory monocytes. LPMs, instead, originate in the fetal yolk sac and undergo to proliferation in situ.  
 
In the steady condition, peritoneal cavity includes a wide variety of immune cells and 
the two subpopulations of macrophages represent about 30-35 percentage of total cells. 
However the presence of an inflammatory or infectious stimulation leads to a dramatic 
change in the number and in the percentage of each subpopulation. Modifications in the 
composition of the peritoneal cavity include the disappearance of LPMs, the increase in 
the number of SPMs and a massive recruitment of circulating monocytes.  
These changes occur  during hypersensitivity reactions and during the process of acute 
inflammation; the increase in the number of SPMs and monocytes is to be correlated 
with the renewal and improvement of the immune conditions of the peritoneal cavity. 
In conclusion, we can say that the SPMs and their precursor (circulating inflammatory 
monocyte) are the main population present in stimulated peritoneal cavity, in fact this 
subpopulation has a pro-inflammatory functional profile while LPMs seem have a role 
in the maintenance of the peritoneal cavity in physiological conditions [98]. 
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1.2.2.2 Microglia 
Microglia are myeloid cells that populate the parenchyma of the central nervous system 
(CNS), representing 5%-12% of the total number of cell depending on the brain region 
[100-101] and were firstly identified in 1919 [102-103]. 
Microglia derive from yolk sac progenitors that colonize the neuroepithelium in early 
stage of embryogenesis [104], acquiring their definitive characteristics, in terms of 
numbers and phenotype, immediately after birth; although a peak of microglia 
proliferation has been demonstrated at early postnatal stages [105-106]. 
Microglia population is maintained locally by self-renewal, without the contribution of 
bone-marrow-derived progenitors [104, 107-108], even though the mechanisms that 
regulate microglia proliferation in steady state are unclear. Some studies reported the 
involvement of transcription factor PU.1, CSF1 and IL-34 in the regulation of microglia 
proliferative pathway [109]. 
Microglia physiological activity includes most of the biological properties that are 
typical for peripheral macrophages, although their developmental origin and 
anatomical distribution allows these cells to perform distinctive immune and 
neuromodulatory functions in the CNS. Through their physical and biochemical 
interactions with neurons, microglia are able to sense and remodel neuronal activity, 
support neurogenesis, and maintain CNS homeostasis. Microglia constantly scan the 
microenvironment to detect and remove neurotoxic substances or inflammatory 
mediators. Microglia phagocytic activity is essential during development (pruning 
microglia), removing supernumerary synapses in some neuronal pathways [110] 
(Figure 13). 
 
 
 
 
 
 
 
 
 
Figure 13. Functions of microglia in the healthy brain. Taken from Gomez-Nicola and Perry., 2015 [111]  
The population of microglial cells is maintained by self-renewal. Surveillant microglia sense and remodel neuronal 
activity, support neurogenesis, and maintain CNS homeostasis.  
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1.2.3 Macrophage self-renewal 
Although it was considered that the tissue macrophages were not able to divide and 
renew themselves, several recent studies have shown that it is possible to maintain a 
homeostatic number of tissue resident macrophage population, which undergoes to 
local proliferation, without the contribution of circulating monocytes or other 
hematopoietic precursors. This phenomenon ensures an adequate number of cells in the 
tissue, even if it  has been demonstrated that following a severe depletion of tissue 
macrophages, monocytes are able to repopulate in a short time the deficient area. 
An exception is represented by intestinal macrophages that originate from bone 
marrow precursors and are constantly supplied by circulating monocytes [112-113]. 
During inflammation,  inflammatory macrophages derive from circulating monocytes 
derived from bone marrow that are recruited to injury site. These cells show a short 
half-life and not proliferate. However some studies demonstrated that both resident 
macrophages and monocyte derivated cells are able to self-renew in response to IL-4 or 
during helminth infection [119, 122] and in zymosan peritonitis model [114], leading to 
an increased number of inflammatory macrophages. Furthermore, it has been 
demonstrated that lesional macrophages that derived from bone marrow precursors 
proliferate in a murine model of atherosclerosis and this mechanism involved the 
scavenger receptor SR-A [115].  
It has been suggested that while the common functions of macrophages, such as 
phagocytosis, may also be implemented by monocytes that migrate in the tissue, the 
more specific functions, for example, the antigen presentation, appear to be possessed 
exclusively by those cells that are renewed locally [94]. 
Different soluble factors regulate proliferative pathway of macrophages (Figure 14).  
The main factor that  regulates the macrophage proliferation in the tissues is the growth 
factor CSF1, which acts binding its receptor CSF1R. CSF1R signaling is essential in 
several aspects of macrophage biology [116] and is mediated by CSF1 but, also, by IL-
34.  CSF1R signaling is involved both in homeostatic macrophage maintenance and 
proliferation [112, 117-119]  and in macrophage inflammatory renewal [114]. CSF2, 
instead, plays an important role in lung alveolar macrophage homeostasis and self-
renewal [120-121]. Recently some studies have shown that even interleukin 4 (IL-4) is 
able to promote the proliferation of these cells, through a mechanism independent of 
CSF1. [119,122]. 
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Figure 14. Soluble factors that modulate tissue resident macrophages. Taken from Fejer et al., 2015 [123]  
Embryonic macrophages from the yolk sac and fetal liver self-renew in homeostatic conditions and are driven by M-
CSF or GM-CSF. Inflammatory macrophages of embryonic origin also self-renew 
 
 
1.2.3.1 Macrophage proliferation induced by CSF1 
An essential regulator of macrophage homeostasis is CSF1 (macrophage colony-
stimulating-factor), so defined since it is able to promote in vitro the growth of 
macrophages derived from bone marrow progenitor cells [124] . It is the main factor 
involved in the survival, proliferation, differentiation of all mononuclear phagocytic 
cells, thus, also dendritic cells, osteoclasts and microglia in addition to macrophage cells 
[125].  
There are three major isoforms of CSF1 protein, that derived from alternative 
transcripts: one secreted as proteoglycan is the predominant form, one secreted as 
glycoprotein and one anchored on the surface of cells that, however, can be released 
through a proteolytic cleavage [125]. 
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CSF1 is produced locally in stroma tissue, although during inflammation can be 
produced by macrophages themselves and acts by binding to its receptor CSF1R or FMS 
(c-fms), that is a member of the family of tyrosine kinase present in macrophages. 
 
Recently it has been observed that the activation of CSF1R receptor requires also a 
second ligand: interleukin 34 (IL-34). Computational studies showed that IL-34 is able 
to bind different region of the receptor [126]; in fact Chihara et al., have identified a 
monoclonal antibody able to bind to CSF1R receptor blocking the binding of CSF1, but 
not of IL-34 [127]. The binding of IL-34 in the extracellular domain of the receptor 
induces the dimerization and autophosphorylation of the intracellular part of the 
receptor, that induces a cascade of intracellular signals, with activation of protein kinase 
PI3K and MEK, able to regulate the production, the survival, and the functions of 
macrophages. 
CSF1 exerts its functions on monocyte-macrophage cells both in bone marrow and in 
the peripheral tissues. In the bone marrow CSF1 is able to promote the differentiation of 
myeloid precursors in monocytes, mostly cooperating with other factors such as GM-
CSF, IL-3, INF-γ. In other tissues, it controls proliferation, differentiation and survival 
of tissue macrophages, regulating the density of tissue resident population in the steady 
state, but, also, in response to an acute infection [125].  
 
1.2.3.2 Macrophage proliferation induced by IL-4 
IL-4 is a multifunctional cytokine that acts as a potent regulator of immunity; it is 
secreted primarily from CD4+ T lymphocytes belonging to the Th2 subpopulation, mast 
cells, eosinophils and basophils. It has been discovered initially by Howard and Paul, as 
a "co-mitogen" for B lymphocytes, later it was discovered its importance in the survival 
of leukocytes both in physiological and pathological conditions and in cell 
differentiation of naïve T cells stimulated by antigen, leading to produce by themselves 
these and other cytokines such as IL-5, IL-10, IL-13. Moreover, IL-4 has important role 
in the regulation immunity mediated by Th2 cells. It is also involved in the switching of 
IgE in B cells [128], tissue repair and alternatively activation of macrophages [129]. The 
inflammatory process that takes place in response to helminth infections or in allergy 
leads to the recruitment of various cells able to produce IL-4 including Th2 cells. 
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Recently it has been demonstrated that, during parasitic infections, there is a vast 
increase in resident macrophage number in infected tissues, which is due to a 
proliferation in situ of resident macrophages without the contribution of circulating 
monocytes. This local proliferation of these cells is regulated by IL-4 produced mostly 
from Th2 cells. This is demonstrated by the fact that following a IL-4  intraperitoneal 
injection in mice there is an increase in the local proliferation of macrophage cells for 
more than four days, and this effect is comparable to the one which occurs during 
infection with the parasite [130]. In addition macrophages that are locally generated are 
characterized by an alternative phenotype (M2). 
Moreover, it was estimated that following IL-4 administration, this local proliferation of 
resident macrophages occurs in all tissues, including liver [130], lung and spleen [119]. 
The mechanism by which this occurs is independent of CSF1R and depends on  IL-4 
receptor (IL-4Rα) that through PI3K/Akt signaling regulates the proliferation as well as 
the alternative activation of macrophages. In fact this does not occur in mice lacking   
IL-4Rα. 
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1.2.3 Macrophage activation 
Macrophages are characterized by high plasticity: in fact they are able to take part in 
different processes such as inflammation, defense against pathogens and tissue repair. 
This is due to their peculiarities to change their morphology and their functional 
characteristics in response to various types of stimuli, both endogenous and from the 
external environment. 
Under normal conditions, macrophages are in a quiescent state, but they can undergo to 
activation as a result of appropriate molecular signals from surrounding 
microenvironment. These signals are typically produced by innate immune cells and 
lead to long-term alterations in macrophages [130]. Furthermore, macrophages 
themselves can also produce some factors that influence their own physiology. 
According to the current classification, macrophages are functional grouped in two 
main phenotypes (Figure 15): the "classical" activation (M1), and the "alternative" 
activation (M2) [131, 239]. However these are two extremes of a series of phenotype that 
macrophages can assume. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Macrophages polarization and functions.  
Schematic representation of M1 and M2 macrophage polarization phenotypes and functions.  
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1.2.3.1 M1 macrophage activation 
M1 macrophages are involved in the initial phase of the inflammatory response and 
provide to the elimination of invading microorganisms through production of reactive 
oxygen intermediates (such as O2- OH-), nitrogen (as NO-, NO2-, ONOO-),  cytokines 
(IL-1 beta, TNF alpha, IL-6) and chemokines (CXCL11). Since this was the first 
antimicrobial mechanism of macrophages recognized, it was called classical 
macrophage activation or M1 [132]. 
Since there isn’t a discrimination of microbial targets and host tissue, M1 macrophages 
can lead to tissue damage as a side effect of their defense activity. Thus, although it is 
an essential event for the organism integrity and  protection from external attacks, the 
inflammatory response requires a strict regulation in order to eliminate the dangerous 
agent without causing damage to the body itself. 
The classical activation of macrophages is induced by the recognition of molecules 
associated with the presence of pathogenic microorganisms, such as the bacterial 
lipopolysaccharide (LPS), component of the cell wall of the gram-negative bacteria, and 
TLR4 ligand or peptidoglycan. Even helper Th1 cells, CD8 + cytotoxic T cells (Tc1) and 
Natural Killer (NK) cells [133] can activate macrophages through the production of 
interferon-γ (IFN-γ), as well as molecules associated to a damage of the cells, such as 
intracellular proteins or nucleic acids.  
M1 macrophages have increased capacity for presenting the antigen, elevated synthesis 
of pro-inflammatory molecules such as interleukin IL-1, IL-6, IL-12, IL-1β, tumor 
necrosis factor alpha (TNF) and toxic mediators such as nitric oxide (NO); moreover, 
they have an increased phagocytic activity mediated by the complement. 
Through this activation, macrophages acquire a bactericidal capacity, especially against 
intracellular pathogens [134]. 
In general, the classically activated macrophages are more commonly associated with 
disease characterized by low-grade of inflammation, such as atherosclerosis and type 2 
diabetes (T2D) [135] and are involved in the immunopathology that occurs during 
several autoimmune diseases, such as rheumatoid arthritis [136] and inflammatory 
bowel disease [137]. The silencing of genes that promote the classical activation, such as 
the gene encoding TLR4, leads to an improvement of these diseases in some murine 
models.  
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1.2.3.2 M2 macrophage activation 
The alternative activation of macrophages, or M2, usually occurs in a second time 
compared to the M1 state during inflammation process, and exerts anti-inflammatory 
effects leading to tissue repair. 
M2 macrophages are able to block the action of M1 macrophages and produce 
important factors that are involved in the repair and remodelling of damaged tissue 
and promote vascularization [139], regulating angiogenesis. They are also involved in 
the regulation of immune response and tumor progression [140]. 
The molecules able to  induce M2 macrophage polarization are various and include 
glucocorticoids, cytokines produced mainly by Th2 such as IL-4 and IL-13, IL-33, IL-21 
or by transforming growth factor β1 (TGFβ1).  Also CSFs seem to be important in 
promoting  M2 phenotype [141-142].  
The M2 phenotype, promoted by Th2 is also essential to control parasite infection, 
including helminthes, protozoa and fungi, as well as contributing to the states allergic 
and increasing susceptibility to other pathogens.  
These macrophages produce various proteins involved in the repair, healing, 
angiogenesis, cell proliferation, which may be used as markers for identify their 
presence. Among the markers used for their identification there are: Arginasi1 (Arg1), 
YM1 (or Chi3l3), Fizz1 (or RELM-α), mannose receptor (MR), VEGF and IL-10. 
The classification of macrophages in M1 and M2 groups was further extended by 
Mantovani and collaborators; thus, on the basis of the different signals that activate 
macrophages, alternative polarized macrophages can be classified into subgroups with 
specific phenotype and functions, called M2a, M2b, and M2c [134, 143]. 
The M2a phenotype can be produced in vitro by exposing macrophages to IL-4 or IL-13, 
that acting through the common IL-4Rα receptor increase the expression of CD206, 
arginase and TGF-β [145-147]. M2a macrophage state has important role in allergy and 
is involved in the killing and encapsulation of parasites. 
The M2b phenotype is produced, instead by exposure of a combination of IgG immune 
complexes and LPS. Unlike the other M2 phenotypes, characterized by low levels of 
pro-inflammatory cytokines (IL-1, TNF and IL-6), M2b macrophages produce many 
inflammatory cytokines and toxic molecules along with high levels of IL-10 and low 
levels of IL-12 [148-150]. Despite this, the M2b cells protect mice from LPS toxicity [146, 
149] and promote Th2 differentiation and production of humoral antibodies. 
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In vitro exposure to IL-10 or glucocorticoids induces in macrophages the M2c 
phenotype, which it is  characterized by the production of high levels of IL-10 and low 
levels of IL-12, as well as by an increase on the cell surface expression of scavenger 
receptor CD163 [151-153]. M2c phenotype promotes the "switching" of macrophages M1 
towards M2 and is induced by adenosine A2A receptor. It is characterized by the 
production of high levels of IL-10 and VEGF, a growth factor of vascular endothelium, 
that is able to promote angiogenesis. [134]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Macrophage polarization. Modified from Zanluqui et al., 2015 [154] 
Macrophage micro-environment stimuli define differential macrophage polarization via classical activation (M1) or 
alternative activation (M2). Pathogen-derived LPS alone or in combination with IFN-γ leads to classical activation of 
M1 macrophages, which improves microbicidal activity and secretion of pro-inflammatory mediators. According to 
the host-parasite microenvironment, alternative macrophage activation could be subdivided into three 
subpopulations. M2a differentiation is promoted by IL-4 or IL-3, and this subpopulation is associated with Th2 
response, allergy process, internalization, and parasite killing. M2b is related to the presence of immune complexes, 
TLR or IL-1R agonists, and promotion of immunoregulation. Glucocorticoids and IL-10 secretion lead to 
differentiation into M2c, which also induces immunoregulation, tissue remodeling, and repair. 
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M2 macrophage actions seem favorable for the protection and restoring a damage in the 
body. Moreover, macrophage alternative activation is generally associated with the 
protection against diseases in which the classical activation is pathogenic. However, the 
activation of alternatively polarization can be deleterious in other pathologies, in 
particular cancer [138]. In fact, they are involved in the complex mechanism that leads 
to the development and growth of tumors, and, in particular, in the invasion and 
metastasis of the tumor: these macrophages are defined as TAMs (tumor associated 
macrophages) [145]. 
The relationship between the activation of macrophages phenotypes observed in vitro 
and the functional states of macrophages in pathological condition in vivo is a topic of 
debate in progress. 
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1.3 Estrogen action on macrophages in physiology 
The influence of estrogen on immune and inflammatory processes initially came to light 
after a series of clinical observations. Humans show strong sex differences in immunity 
to infection and autoimmunity, suggesting that sex hormones modulate  immune 
responses. 
 In fact, it is widely accepted that females have a more efficient immune system than 
males [155-157] and this difference in the inflammatory response may explain the 
significantly lower incidence of infections and resultant mortality in women than in 
men. This more enhanced inflammatory response in women represents an advantage in 
infection and sepsis, but, on the other hand, is a disadvantage in immune response 
against self, as demonstrated by their higher incidence of autoimmune diseases, such as 
rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis [158-162] 
(Figure 17). Moreover females more rapidly reject skin allografts than males, but suffer 
lower rates of some tumors, such as colorectal [163] , renal cell [164]  and liver 
carcinomas [165].  
In accordance to this proofs, estrogens have been shown to be protective in several 
diseases characterized by a relevant inflammatory component, such as atherosclerosis, 
wound inflammation and asthma. Indeed, epidemiological and immunological 
evidence has been shown that menopause, menstrual cycle and pregnancy are 
important influencing factors in the etiology and course of chronic inflammatory 
diseases [166-169]. 
Particularly, the onset of menopause, when the levels of circulating estrogens rapidly 
decline, is characterized by an increase of the incidence in women of diseases 
characterized by a relevant inflammatory component (Figure 17). Instead, hormone 
replace therapy (HRT) in postmenopausal women have been demonstrated beneficial 
effects in these conditions, such as  osteoarthritis, multiple sclerosis, atherosclerosis and 
neurodegenerative diseases [170-174].  
Moreover also polymorphisms of estrogen receptor genes affect the incidence of 
different inflammatory pathological conditions [175-178]. 
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Figure 17. Correlations between the relative levels of estrogen and testosterone and the incidence of diseases 
associated with chronic inflammation. Taken from Gubbels., 2015 [179] 
Type 2 diabetes, atherosclerosis, and autoimmunity in men and women between the ages of 30 and 80 years. White 
and shaded columns demarcate periods in the lifespan during which chronic inflammatory and autoimmune 
diseases manifest clinically. A comparison of the incidence of each disease in men and women for each time period 
and disease is indicated.  
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1.3.1 Estrogen as inflammatory regulator 
Many cells of the immune system are target of estrogen action, that through ERs and 
membrane receptor (GPR30) binding modulate development and functions of innate 
immune cells.  
Some studies have reported that ER mRNAs and proteins are expressed by 
hematopoietic progenitors and mature immune cells and have determined their levels 
of expression (Table 4) (as reported in the review of Kowats, 2015 [180]).  
These studies reported that B lymphocytes express highest levels of Esr1 RNA, whereas 
lymphocytes CD4+ and CD8+, natural killer cells and dendritic cells (DC) have 
intermediate levels of expression [181-183]. Monocytes, instead, are those that have the 
lowest levels of RNA expression of Esr1, even if  dendritic cells that derived from 
monocytes have increased levels of expression of Esr1 and Esr2, suggesting that ERs are 
induced during activation of myeloid cells [185]. 
As regards the Th1 and Th2 lymphocytes, they do not have differences in RNA 
expression of ERs, as well as there are no differences in T cells in normal conditions. 
This suggests that the effects of estrogen in these cells do not depend on differences in 
expression of ER receptor. However, evidence demonstrated that naïve T-cells are more 
sensitive to the effect of estrogen [184].  
Regarding the expression levels of Esr2, coding for ERβ, these are very high in B cells 
and dendritic cells, and are very low in all other cell types.  
Bone-marrow derived macrophages and peritoneal macrophages express Esr1 but not 
or very little Esr2 [186-187]. 
Interestingly, there are no differences in the expression of ESR1 and ESR2 mRNA in 
immune cells between men and women or in pre and postmenopausal women, 
suggesting that it is not the change in the number of receptors that lead to alterations in 
immune function and the consequent pathologies associated with menopause, even in 
women in postmenopausal there is an increase in the number of ER in monocytes, as 
compared to monocytes of premenopausal women, that is associated to an altered 
responsiveness to estrogen [184]. It would therefore the different sensitivity of the 
receptor to the hormone to influence its final response. 
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  Human Murine 
Cell type ESR1 (Erα) ESR2 (Erβ) Esr1 (Erα) Esr2 (Erβ) 
B cell yes (+++)b yes (+++) yes  yes  
CD4+ T cell yes (++) yes (++) yes  c 
CD8+ T cell yes (++) yes (++)     
 NK cell yes (++) yes (++) yes  yes  
Plasmacytoid DC yes (++) yes (+++) yes    
Monocyte yes (+) yes (+)     
Monocyte-derived DC yes (++) yes (+)     
BM-derived DC     yes  yes  
Splenic DC     yes  no  
Inflammatory DC CNS       yes  
Peritoneal Macrophages     yes  no  
BM-derived Macrophages     yes  no  
Hematopoietic stem cell yes  yes  yes  no  
Myeloid progenitor     yes  no  
 
Table 4. Expression of estrogen receptors by immune cells. Modified from Kowats S., 2015 [180] 
a“Yes” indicates either RNA or protein expression, depending on the study. “No” indicates that the RNA or protein 
was queried but not found. bPlus (+) marks indicate relative amounts of RNA determined using quantitative. cEmpty 
cells indicate cell types for which actual data showing ER expression was not readily found in literature sear 
 
A lot of works demonstrated that E2 and ER signaling regulate inflammatory pathways 
of immune cells, specially dendritic cells and macrophages. Particularly, these studies 
showed that low levels of estrogen promote the induction of type I IFN and suggest that 
ERα and IFNs interact to modulate immune response [188-189]. 
Furthermore, E2 affects cytokine production, but its effects depend  on cell types, 
condition in the milieu and estrogen concentration. Some works showed that estrogen 
induces the production of pro-inflammatory cytokines in response to TLR ligand 
activation in DCs and macrophages [190-191]. However a lot of studies demonstrated 
that estrogen at higher physiological or supra-physiological levels induces an anti-
inflammatory response that attenuates inflammation [192-194]. In addition, estrogen 
leads to the inhibition of nuclear factor kappaB (NF-κB) signaling through different 
mechanisms such as the displacement of coactivators, enhancing IκBα levels, the 
inhibition of NF-κB nuclear translocation and the repression of Iκbkg [195-200]. 
Moreover ER signaling modulates also hematopoietic progenitors and their 
proliferation, regulating number and type of immune cells [201]. 
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1.3.2 Effect of estrogen on macrophages 
Estrogen modulates through autocrine and paracrine mechanisms various activities of 
macrophages, such as cell differentiation and maturation and regulation of 
proinflammatory cytokines and/or production of immunosuppressive and growth 
factors.  
The mechanisms involved in the regulation of inflammatory response mediated by 
estrogens are different; the ERs activation in macrophages leads to the regulation of 
gene transcription and the modulation of non-genomic pathways [202]. 
The activation by estrogen of ERs, is able to reduce the synthesis of pro-inflammatory 
molecules [200, 203], control mitochondrial respiratory and mitosis, induce the 
degradation of damaged proteins by  proteasome [204], reduce monocytes apoptosis 
and activate  hypoxic genes [205].  
The main mechanism mediated by ERs involves the modulation of NF-κB pathway and 
regulates the transcription of cytokines and other inflammatory mediators [155, 200]. In 
fact, in presence of powerful inflammatory stimuli (such as LPS), estrogen blocks NF-κB 
nuclear translocation and modulating p65 activity; this effect is mediated by PI3K 
signaling [200]. Pro-inflammatory cytokines that are inhibited by estrogen through this 
mechanism are, for example, IL-6, IL-8, TNFα, MCP-1 and IL-1β. Some in vitro studies 
showed that estrogen, on the contrary, stimulates the secretion of anti-inflammatory 
cytokines such as IL-4, IL-10 and TGF-β [169]. However, as previously cited, the effects 
of estrogen on macrophage cytokine production is strongly dependent on hormone 
concentration, microenvironment and the presence or absence of inflammatory stimuli. 
In addition to regulate cytokines expression, estrogen modulates macrophage functions, 
regulating other important inflammatory factors. In fact, estrogen at proestrus to 
pregnancy levels inhibits NO formation in mouse macrophages (RAW 264.7) [206] and 
the reactive oxygen species (ROS) production in primary rat microglia and microglial 
cell line (N9) [207].  
Also adhesion molecules play key role in inflammation, attracting inflammatory cells to 
inflamed sites. It has been demonstrated that E2 at proestrus to pregnancy levels is able 
to inhibit monocyte adhesion to endothelial cells in an in vitro model of the vasculature 
[208-209]. However, low levels of estrogen can produce different effect: some studies 
showed that E2 is able to induce the expression of adhesion molecules [210-211]. 
Apoptosis, instead, in inflammatory condition has both beneficial effects, inhibiting 
autoaggresive cells, and deleterious results, hampering repair process and tissue 
 
 
39 
 
regeneration. It has been demonstrated an antiapoptotic action induce by estrogen in 
murine microglial cells (N9), confirmed in vivo [212-213]. Although estrogen promote 
antiapoptotic effect in immune cells, it is able to have proapoptic effect in osteoclasts 
[214]. 
Furthermore, estrogen at proestrus to pregnancy levels promotes angiogenesis and 
increases the production of vascular endothelial growth factor (VEGF) in different cell 
types, among which macrophages [206, 215-216]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Estrogen pro and anti-inflammatory effect on different cell type. Modified from Straub R., 2007 [169] 
On the y-axis, the concentration of estrogens is given. Depending on the concentration of estrogens, factors in green 
boxes are stimulated, and factors in orange boxes are inhibited by estrogens. DC, Dendritic cell; MΦ, 
monocyte/macrophage 
 
 
In addition to classic nuclear receptors ERs, also membrane receptor GPR-30 present in 
macrophages seems to modulate the anti-inflammatory effects of estrogen. An in vitro 
study has shown that short treatments with 17β-estradiol are able to reduce the 
expression of TLR4 in a short time, attenuating the response of cells to this 
inflammatory stimulus [217]. 
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1.3.2.1 Estrogen action on M2 macrophage activation 
Despite the action of estrogen on M1 macrophage activation is well documented, as 
previously described, the capacity of estrogen to modulate M2 macrophage polarization 
is still little known and most of the experiments on this topic are performed in vitro. 
It has been shown that 17-βestradiol regulates phagocytic activity of microglia under 
hypoxic conditions and promotes the switch from an M1 toward an M2 phenotype of 
primary rat microglial cultures and BV2 cells [218]. Moreover estrogen is able to 
modulate microglia activation, down-regulating the expression of COX2, iNOS and NO 
production in BV2 cells following LPS stimulation [219] and transient hypoxia [220]. 
The effect of estrogen on M2 macrophage polarization is evident in the animal model of 
wound healing. Some studies have demonstrated in a murine incisional model of 
wound healing in ovariectomized animals that, while ovariectomy impairs macrophage 
alternative activation, that is essential to resolve inflammation, estrogen treatment is 
able to reverse this effect. Indeed, estrogen promotes macrophage switch toward M2 
phenotype, driving wound repair, angiogenesis and remodelling [221] and this 
hormone action is mediated by ERα [222]. 
Moreover, a recent study performed in our laboratory showed in an in vitro model that 
estrogen, following a proinflammatory stimulus, such as LPS, decreases the duration of 
proinflammatory phase and accelerates its progression to the resolution phase. This 
occurs because estrogen modifies intrinsic and extrinsic programs in macrophages, 
promoting a rapid transition of these cells from a pro-inflammatory phenotype to 
immunomodulatory M2c state, also called "acquired deactivation" (AD) [141]. Estrogens 
exerts this effect through the regulation of STAT3 and SOCS3 pathway and promote 
inflammation progression, by regulating the production of IL-10 that is the main 
marker of macrophages with M2c polarization. M2c macrophages secrete some factors, 
such as VEGF or TGFβ, that lead damage repair, restructuration and remodeling of the 
connective tissue, angiogenesis and restore tissue homeostasis [223]. 
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1.3.2.2 Macrophage ERαKO 
The studies performed using cell-specific ablation of ERα in monocyte/macrophage cell 
lineage have led to a more comprehensive knowledge of the role of estrogen in these 
cells. 
A study demonstrated that E2, thorough ERα activation, enhances in vivo 
proinflammatory response of peritoneal macrophages following TLR4 activation, 
increasing the expression of IL-1β, IL-6, IL-12p40 and NO synthase production, and this 
mechanism is due, at least in part, to the inhibition of PI3K/Akt pathway [191]. 
Another work investigated the role of estrogen in obesity-induced insulin resistance 
and showed that E2 is essential for the repression of inflammation, maintenance of 
macrophage metabolism and macrophage phagocytic ability. In fact, ERα macrophage 
deletion promotes different aspects of metabolic syndrome, leading to glucose 
intolerance, insulin resistance, tissue inflammation and obesity [187]. Moreover, ERα 
deletion accelerates atherosclerotic lesion development in LDL receptor-KO female 
mice, this is probably due to a diminished expression in ERαKO macrophages of Tgm2 
(protective agent against atherosclerotic lesions), ApoE and Abca1, which exert 
atheroprotective action, a reduction of fatty acid oxidation rates and an increase of 
inflammatory gene expression [187]. 
Few studies showed that estrogen action mediated by ERα is important to promote 
macrophage alternative activation in some experimental animal model [187, 222]. 
Altogether these studies suggest that estrogen induces a more efficient inflammatory 
response in macrophages in order to accelerate the resolution phase. 
This evidence indicates that molecular players of estrogen signaling in macrophages 
may represent important pharmaceutical targets to modulate inflammation in several 
pathological conditions. 
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1.4 Relevance of estrogen action on macrophages in pathology 
During tissue development, macrophages play a key role in shaping and remodelling 
the architecture of many of them, such as brain, gland, bone and mammary tissues. 
After development, macrophages maintain  important roles in these tissues, modulating 
homeostasis and tissue physiology, regulating several tissue features, including 
metabolism and neural connectivity, and detecting damage. Since their trophic and 
regulatory functions are often subverted by chronic inflammatory insults, they are 
involved in many diseases often related with aging (Figure 19).  
On the other hand, estrogen play a key role in pathology characterized by a relevant 
inflammatory component, modulating macrophage inflammatory response and 
functions, as previously described. 
Thus, I focused my attention on some pathologies where estrogen-macrophage 
interplay may be crucial for disease development progression and where the 
modulation of estrogen signaling in macrophages might be a therapeutic strategy to 
develop new drugs. Particularly, I focused on diseases, such as endometriosis and 
cancer, specially ovarian cancer, where peritoneal macrophages are involved in the 
pathogenesis, and neurodegenerative diseases, where microglia play important role. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Macrophage biology in development, homeostasis and disease. Figure modified from Wynn T.A. et al., 
2013 [225]. Diseases in which are involved the different tissue resident macrophages.  
Peritoneal macrophages Endometriosis 
Ovarian carcinoma  
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1.4.1 Endometriosis 
Endometriosis is a gynecologic disease that affects women's fertility. It is a chronic 
inflammatory condition driven by estrogen and progesterone hormones characterized 
by endometrial cells that colonize and grow in peritoneal cavity, but also in other 
abdomen organs, such as gut or bladder. These endometrial cells produce high 
quantities of chemotactic and angiogenic factors that recruit macrophage and other 
immune cells and promote neovascularization [226-228] 
Several mechanisms are involved in this process, such as anatomical and mechanical 
changes, immune and inflammatory factors, ovarian reserve alterations. 
 It was been observed a negative role of M2 macrophages in endometriosis, in which 
they seem to be crucial in promoting and developing its characteristic injuries [229]. 
Estrogen, instead, plays important role in endometriosis. Indeed, the ectopic growth 
and persistence of endometrial tissue in pelvic area are supported by estrogen, as well 
as biological changes and clinical events associated to the disease [230]. Moreover 
estrogen strongly affect inflammation [226-228]. Further evidence of estrogen-
macrophages interplay is brought by in vivo model of peritoneal macrophages depletion 
leading to tissue growth and development reduction of the ectopic lesion [231]. 
Moreover, immunological changes can be detected; patients’ peritoneal liquid is 
characterized by high level of pro-inflammatory cytokines, such as TNF-α [232-233], IL-
6 [234], IL-12 [235] , IL-8, IL-10 [232] and other inflammation mediators and cells, in 
particular activated macrophages [236-238]. Endometrial macrophages appear to be also 
involved in red blood cells and cellular endometrial debris elimination through 
phagocytosis and in promotion of angiogenesis through trophic factors production, in 
agreement with M2 phenotype [131, 239]. Indeed , in in vivo murine model of the 
pathology, as well as in sick women, peritoneal macrophages express high levels of 
CD206 and CD163, typical M2 markers. These cells release growth factors, such as 
VEGF-α and HGF, in response to ovaric steroids. In particular, HGF production is 
inhibited by estrogen antagonist administration. Mitogenic effect of HGF is explicated 
by  interaction with c-MET receptor on peritoneal macrophages, promoting their 
proliferation and the development of endometrial pathology [241]. Moreover, through 
the release of chemotactic factors such as MIF,  these macrophages lead to their 
accumulation in the peritoneal cavity, with consequent exacerbation of inflammation 
[242]. Thus, macrophages ability of remodeling and regenerate tissues is responsible of 
their involvement in pathologies characterized by persistent tissue reshaping [243-244].  
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Local hypoxia and iron overload might be triggering factors of macrophages alternative 
activation, although the precise mechanism is still unclear.  In conclusion, the purpose 
of alternative peritoneal macrophages activation is to counteract inflammation in the 
peritoneal environment, but, in some circumstances, it can lead  to ectopic endometrial 
tissue growth and vascularization [229]. 
 
 
1.4.2 Cancer 
Estrogens play a critical role in the development of  tumors in several tissues, such as 
breast, prostate and endometrial tissue [245-248] and is crucial in disease progression. 
On the other hand, macrophages plenty populate tumors [249] . Originally was thought 
that macrophages had anti-tumor activity, but clinical and experimental evidence 
showed that macrophages have tumorigenic effects, promoting tumor initiation, 
progression and metastasis [250]. During persistent infection, macrophages increase the 
production of inflammatory cytokines, such as IFN-γ, TNF-α and IL-6, sustaining a 
state of chronic inflammation that seems to be crucial for tumor initiation and 
promotion [251]. Once tumors become established, macrophage differentiate as tumor-
associated macrophages (TAMs) switching from an immunologically active phenotype 
towards  an immunosuppressive phenotype capable of supporting tumor progression 
and malignancy [250]. TAMs are involved in tumor-cell migration, invasion and in the 
angiogenic response essential for tumor growth [250,252,253]. These events lead to the 
formation of metastasis, promoting tumor cells escape into the circulatory or lymphatic 
system. Some evidence suggests that macrophages acquire these activities in response 
to CSF1, IL-4 and IL-13, that are  present at high levels in tumor microenvironment, 
leading to tumor-cell invasion and intravasation in mammary cancer [254]. 
Ovarian carcinoma is sustained by E2 production by stromal cells and is characterized 
by the dissemination of cancer cells into the whole peritoneum. Some evidence 
indicates that ovarian tumor progression is orchestrated by the interplay between 
tumor cells and peritoneal  macrophages, as well as other immune cells. It has been 
recently shown that ovarian tumor-derived TGF-β2 and CCL2 stimulate normal 
peritoneal macrophages to acquire features of TAMs [255]. TAMs promote tumor 
progression by suppressing adaptive immunity and producing proangiogenic factors, 
such as Vegfα [256-257]. 
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In this scenario estrogen might support tumor progression and growth, promoting 
macrophage alternative activation and angiogenesis. In fact, in the high-grade serous 
ovarian cancer (HGSC) E2 promotes tumor growth, inducing alternative activation of 
macrophages and increasing their infiltration in the tumor area []. 
However, interestingly, a study on hepatocellular carcinoma (HCC), a malignant tumor 
that affects mainly males, showed that the 17β-estradiol inhibits development of 
malignant cells, through the control of macrophages polarization by blocking the 
alternative activation [258]. In particular, the hormone explicates its repressive action on 
ATP5J factor(ATPase-coupling factor 6) by interaction with ERβ. ATP5J is a component 
of ATPasi complex, an enzyme that allows ATP synthesis from ADP and inorganic 
phosphate (Pi), by exploiting proton-driving force. In this way JACK1-STAT6 signaling, 
responsible of alternative activation, is inhibited [258]. 
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4.3 Neurodegenerative diseases 
Several evidence shows that neuroinflammation mediated by microglia is a critical 
contributor to the pathogenesis of neurodegenerative diseases [259-261]. 
Microglia persistently activated and their production of inflammatory cytokines, ROS 
and immune mediators lead to the maintenance of inflammatory milieu in different 
degenerative disease, such as Alzheimer’s Disease (AD), amyotrophic lateral sclerosis 
(ALS) and Parkinson’s Disease (PD) [259-260, 262], and contribute to neuronal death. 
Moreover it has been demonstrated a marked expansion of M1 activated microglia, 
without the contribution of bone-marrow-derived cells, during the course of these 
diseases, particularly in ALS, PD and Huntington’s disease (HD) and AD, especially 
around plaque of amyloid β (Aβ) [109. 263-265]. This local proliferation of activated 
cells leads to a detrimental contribution of microglia to the progression of the pathology 
[109, 266]. 
On the other hand, it has been demonstrated that M2 microglia ameliorates several 
aspects of neurodegenerative diseases in different animal models. For example, M2 
microglia showed beneficial role in AD mouse model [267-269], maybe also increasing 
the clearance and the degradation of Aβ, and potentially had protective role in the 
incidence and progression of MS, since M2 polarized cells reduce the severity of the 
pathology in an experimental model of autoimmune encephalitis (EAE) [270-272]. 
Estrogens, instead, exert anti-inflammatory and neuroprotective effects in CNS in acute 
and chronic brain diseases [218]. Several studies have demonstrated a neuroprotective 
function of E2 in animal model of neurodegenerative diseases, traumatic brain injury 
and ischemic stroke [168, 273-278]. This protective effect of estrogen is due, at least in 
part, to its ability to modulate microglia activation, inhibiting M1 macrophage 
phenotype and promoting a M2 pro-resolving state [219-220, 279]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
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Despite the evidence of an important role of estrogen in inflammation and its relevance 
in the regulation of physiology and pathology, the molecular and biological details of 
estrogen action in macrophages are still poorly understood.  
Thus, the aim of this study was to investigate the effects induced by estrogen alone on 
resident macrophages in healthy mice. To this purpose, we obtained peritoneal 
macrophages exposed to physiological and pharmacological surge of estrogen in vivo. 
This comprehensive study allowed us to identify the molecular targets and the 
biological role of the estrogen-macrophage interplay in female physiology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
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3.1 Animal models and treatments 
C57BL/6 female mice at 4 months of age were supplied by Charles River Laboratories; 
ERαKO female mice were obtained from P. Chambon, IGBMC, Strasbourg, France [305]. 
Animals were allowed to food and water access ad libitum and kept in temperature-
controlled facilities on a 12-hour light and dark cycle. Animals were housed in the 
animal care facility of the Department of Pharmacological and Biomolecular Sciences at 
the University of Milan. The phase of the reproductive cycle in female mice was 
assessed by blind analysis of vaginal smears mounted on glass microscope slides and 
stained with May-Grünwald-Giemsa method (MGG Quick Stain Kit; Bio-Optica) 
according to the manufacturer’s protocol. 17β-estradiol (E2; Sigma-Aldrich) was 
administered by a 100 μL s.c. injection of 5 μg/kg E2 dissolved in corn oil by o/n stirring 
in the dark at room temperature in order to obtain physiologic plasma levels of E2 [306]. 
Since previous laboratory investigation demonstrated that s.c. injection of corn oil did 
not significantly affect macrophage parameters and expression of gene analyzed;  
control ME animals were processed immediately after their identification in ME phase 
in order to not have an influence of the fluctuating levels of endogenous hormones 
during estrous cycle. Ovariectomy (ovx) or sham surgery was performed under mild 
anesthesia obtained by s.c. injection of 50 l solution of ketamine (93.6 mg/kg, Ketavet 
100; Intervet) and xylazine (7.2 mg/kg, Rompun; Bayer). At the specified time points, 
animals were euthanized by intraperitoneal (i.p.) injection of lethal ketamine and 
xylazine solution (150 and 12 mg/kg, respectively). Animal groups (n=3) for the RNA 
sequencing experiment were given an estrogen-free diet (AIN93M; Mucedola) 2 weeks 
before and throughout the experiment. Animal investigation has been conducted in 
accordance with the ethical standards and according to the Declaration of Helsinki and 
according to the Guide for the Care and Use of Laboratory Animals, as adopted and 
promulgated by the US National Institute of Health, and in accordance with the 
European Guidelines for Animal Care and Use of Experimental Animals. Experiments 
were approved by the Italian Ministry of Research and University and by the Ethical 
Committee of the University. 
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3.1.1 Zymosan peritonitis model 
 For the zymosan peritonitis model, 4 weeks after sham/ovx surgery mice were injected 
i.p. with 1 mg of Zymosan (Sigma-Aldrich) in 1 ml of 0.9% NaCl, while control mice 
received physiological solution alone. Animals were sacrificed after 12, 36 and 60 h. 
Ovx mice were treated with veh or E2 by repeated injections given 3 h before zymosan 
and 16 h before sacrifice at 36 and 60 h. The numerosity of each control or treated group 
was n=3. Macroscopic and weight analyses of uterine tissue were used to confirm the 
success of ovx and E2 treatments. 
 
3.1.2 BrdU injection 
 For in vivo BrdU labelling experiments, mice were injected i.p. with 30 ul of a 10 mg/ml 
solution of BrdU (Sigma-Aldrich) dissolved in 0.9% NaCl. Animals were sacrificed 2 h 
after BrdU injection (n=4-6) 
 
3.1.3 Intracerebroventricular injection of IL-4  
Intracerebroventricular (icv) injections were made as previously described [307]. Briefly, 
mice were deeply anesthetized with a subcutaneous injection of a mixture of ketamine 
and xylazine (78 and 6 mg/kg, respectively) and positioned on a specific stand for the 
surgical operation. Injections in the third cerebral ventricle (icv) were performed 
according to specific stereotaxic coordinates (bregma, −0.25 mm; lateral, 1 mm; depth, 
2.25 mm), as previously described [307]. Interleukin-4 was injected in 2.5 μl of 0.9% 
NaCl using a 26S-gage Hamilton Syringe; 250 ng were injected to assess RNA levels. 
Infusions were made at a rate of 0.1 μl in 3 s. The needle was kept in place for 30 s after 
the injection and then removed slowly. Animals injected with the same volume of 
vehicle (0.9% NaCl) alone were used as controls. The skin incision was closed with a 
suture and animals were allowed to recover for 24 hours before sacrifice by a lethal 
ketamine and xylazine solution (150 and 12 mg/kg, respectively). For RNA 
quantification, the right frontal cortex, contralateral to the injection site, were collected, 
immediately frozen on dry ice, and stored at −80°C until RNA preparation. The 
numerosity of each control or treated group was n=12. 
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3.2 Peritoneal and bone-marrow-derived macrophages (BMDMs) 
Peritoneal cells were recovered by peritoneal lavage. Briefly, 5 ml of pre-chilled 0.9% 
NaCl were injected into the peritoneal cavity using a 21G needle, cell suspension 
centrifuged and dissolved in PBS + 0.5%BSA. After counting, peritoneal cells were 
isolated either by incubation with anti-CD11b antibody loaded MicroBeads (Miltenyi 
Biotec) for RNA sequencing, gene expression validations and proliferative index 
analyses, or by anti-CD11b, F4/80 and Ly6C antibodies for cytometry phenotyping or 
macrophage sorting for gene expression analyses. Briefly, 107 peritoneal cells were 
suspended in 90 µL PBS + 0.5% BSA, and 10 µL CD11b MicroBeads were added to the 
cell suspension and incubated for 15 min at 4°C. After washing, cells were resuspended 
in 500 uL PBS + 0.5% BSA and applied to LS Miltenyi columns (Miltenyi Biotec) for the 
magnetic separation procedure. After 3 washing steps, CD11b-positive cells were eluted 
from the columns and counted. Cells were either stored in TRIzol reagent (Invitrogen) 
for gene expression studies or fixed for flow cytometry analyses or plated at the 
concentration of 1 × 106 cells/ml in RPMI medium w/o phenol red with 10% dextran 
coated charcoal-FBS for in vitro assay .  
To prepare BMDMs, bone marrow from the tibia and femur was flushed with RPMI 
(Life Technology-Invitrogen) using a 21 gauge needle. Cells were centrifuged at 1200 
rpm for 5 min at 10°C, seeded in flask cell culture T75 in DMEM+GlutaMAX (Life 
Technology-Invitrogen) supplemented with 10% endotoxin-free FBS, 1% 
penicillin/streptomycin and 1% Na pyruvate and incubated o/n. On the next day, the 
supernatant was collected, seeded at the concentration of 5-8 x 106 cells/dish and grown 
for 6 days in DMEM+GlutaMAX containing 20% endotoxin-free FBS, 30% L929-cell 
conditioned media, 1% penicillin and streptomycin, and 1% Na pyruvate. After 6 days 
BMDMs were harvested with Accutase (Merck-Millipore) and plated at the 
concentration of 5 × 105 cells/ml. On the next day, RPMI medium w/o phenol red with 
10% dextran coated charcoal-FBS was added and cells were treated for 24 h with vehicle 
or E2 at the specified concentrations, with hormone being added in the last 3 hours of 
incubation for the 3 h E2 treatment.  
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3.3 Microglia isolation 
 After 24 h of E2 treatment, brains were dissected and washed in Hank’s Balanced Salt 
Solution (HBSS; Life Technologies); after removing the meninges. Enzymatic cell 
dissociation was performed using Neural Tissue Dissociation Kit P (Miltenyi Biotec), 
following a modified version of the protocol supplied by the manufacturer. Briefly, 
after enzymatic digestion with papain, samples were dissociated mechanically, 
homogenized, and filtered through a 40-μm cell strainer. After extensive washes in 
HBSS, myelin was removed by centrifuging the dissociated brain cells, which had 
previously been suspended in 10 ml of cold 0.9 M sucrose solution, at 850 g and 4°C for 
10 min without braking. Floating myelin and the supernatant were discarded and cells 
were processed for microglia magnetic sorting by incubating with CD11b MicroBeads 
(diluted 1:10 in PBS + 0.05% BSA; Miltenyi Biotec) for 15 min at 4°C; after washings, 
cells were suspended in 500 μl of PBS + 0.05% BSA and applied to a magnetic column to 
purify CD11b+ cells, namely microglia. CD11b+ cells were then processed for RNA 
preparation. 
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3.4 Flow cytometry analysis 
To assess cell proliferation index, CD11b-positive cells obtained from each animal were 
divided in 3 aliquots; 2 aliquots of 2.5x105 cells each were used to detect BrdU and Ki67 
by flow cytometry, the remaining aliquot was used for gene expression. Cells were 
suspended in 2 ml of pre-chilled ACK solution (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM 
EDTA; pH 7.3). For Ki67 staining, cells were fixed in 4% paraformaldehyde for 15 min, 
extensively washed with 125 mM glycine in PBS and permeabilized o/n in PBS 
containing 0,5% Triton X-100 and 1% BSA, at 4°C. Cells were incubated with rabbit anti-
mouse Ki67 antibody conjugated with eFluor660 (eBioscence-Affymetrix) diluted 1:100 
in Incubation Solution (PBS containing 0.5% Triton X-100 and 0.05% BSA) at room 
temperature for 1 h. After extensive washes in PBS, cells were analyzed with a flow 
cytometry system (BD FACS Calibur). For BrdU staining, cells were fixed and 
permeabilized in 70% EtOH for 30 min at 4°C and DNA was denaturated with 2 N 
HCl/0.5% Triton X-100 and incubated 30 min at room temperature. Cells were washed 
with 0.1 M sodium tetraborate (pH 8.5) and incubated with rat anti-mouse BrdU 
antibody (AbD Serotec) diluted 1:100 in Incubation Solution (PBS containing 0.05% 
Tween-20 and 1% BSA). After washes in PBS/1%BSA, cells were incubated with 
Alexa488-conjugated goat anti-rat secondary antibody (1:200 in incubation solution; 
Molecular Probes) for 1 h at room temperature. Cells were extensively washed with 
PBS, resuspended in PI solution (H2O containing 10% NP40, 1 mg/ml RNase A and 5 
µg/ml PI stock; Sigma-Aldrich). Samples were analyzed using FACSCalibur and 
analyzed with FlowJo version 9 software (Tree Star). Animals with no pulse of BrdU 
were used for gating strategy to evaluate nonspecific signals.  
In the sham/ovx animals and zymosan-induced peritonitis model immunofluorescent 
staining of peritoneal cells was performed with V450 anti-mouse CD45, PerCP-Cy5.5 
anti- mouse CD11b, FITC anti-mouse Ly6C, PE-Cy7 anti-mouse Ly6G, PE anti-mouse 
CD11c, PE anti-mouse CD19 (BD Biosciences), AlexaFluor 647 anti-mouse F4/80 (AbD 
Serotec) and PE anti-mouse CCR3 (R&D Systems). Samples were analyzed using FACS 
Canto II and DIVA software (BD Biosciences); gating strategies are reported in 
Supplementary Figure 1. Resolution indices of zymosan-induced peritonitis were 
calculated as previously described [308]. Ly6G-negative CD11b-positive and F4/80-
positive macrophages were sorted using sorter Aria (FACS Aria, Becton Dickinson 
Biosciences) and resuspended in TRIzol reagent for gene expression analyses. 
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3.5 RNA preparation and analysis 
Total RNA was purified using RNeasy minikit protocol (Qiagen), according to the 
manufacturer’s instructions, including a step with deoxyribonuclease incubation. For 
real time PCR, 1 μg RNA (250 ng in peritonitis model and 50 ng in isolated microglia) 
was used for cDNA preparation using 8 U/μl of Moloney murine leukemia virus 
reverse transcriptase (Promega) in a final volume of 25 μl; the reaction was performed 
at 37°C for 1 h, and the enzyme inactivated at 75°C for 5 min. Control reactions without 
the addition of the reverse transcription enzyme were performed (data not shown). A 
1:4 cDNA dilution was amplified using GoTaq®qPCR Master Mix technology 
(Promega) according to the manufacturer’s protocol. The PCR was carried out in 
triplicate on a 96-well plate using 7900HT fast real time PCR system (Applied 
Biosystems) with the following thermal profile: 2 min at 95°C; 40 cycles, 15 sec at 95°C, 
1 min at 60°C. Primer sequences are reported in Supplemental Table 10. Data were 
analyzed using the 2-ΔΔCt method. For RNA sequencing, RNA Quality Control was 
performed on all RNA samples with an electrophoretic run on a Bioanalyzer instrument 
using the RNA 6000 Nano Kit (Agilent). RNA Integrity Number was determined for 
every sample and all the samples were considered suitable for processing based on the 
RNA integrity (RIN > 8). RNA concentration was estimated through spectrophotometric 
measurement using a Nanoquant Infinite M200 instrument (Tecan). Sequencing 
libraries were prepared using the TruSeq™ RNA Sample Preparation Kit (Illumina) 
using 1.8 ug of total RNA as input. Polyadenylated transcripts were purified using 
poly-T oligo-attached magnetic beads. PolyA RNA was fragmented at 94°C for 8 min 
and retrotranscribed using random hexamers. Multiple indexing adapters were ligated 
to the ends of the cDNA and the amount of DNA in the library was amplified with 10 
PCR cycles. Final libraries were validated and quantified with the DNA1000 kit on the 
Agilent Bioanalyzer Instrument. Pooled libraries were sequenced on the Illumina 
Genome Analyzer IIx producing an average of 13 M reads per library. 
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3.6 Bioinformatics analysis 
BaseCall files were converted to FastQ files using Casava 1.8.2. Sequencing reads were 
aligned to the mouse genome (mm10) using TopHat v.2.0.9. Transcripts were 
reconstructed and quantified using Cufflinks v2.1.1 and differential expression analysis 
was performed using CuffDiff [309]. CuffDiff uses the test statistics T = 
E[log(y)]/Var[log(y)], where y is the ratio of the normalized counts between two 
conditions. A t-test is used to calculate the P value for Differential Expression [310]. A 
threshold of 0.05 was applied to False Discovery Rate (FDR) adjusted p values in order 
to select the differentially expressed genes (DEGs) to use in downstream analysis; we 
also included genes with a log2 fold-change (lgFC) > 1 either showing one anomalous 
triplicate FPKM value and an FPKM average value between 1 and 2. Heat map of DEGs 
was made with Genesis software using triplicates mean, after normalization and log2 
transformation. Cluster analysis was performed with the Genesis software tool using k-
means clustering function (k=8) in order to identify group of genes with a similar 
regulation at 3 and 24 h of treatment [311]; genes with lgFC > +/-0.40 were selected. In 
each cluster of genes, the regulatory sequences in 20 Kb around the transcription start 
site were analyzed using iRegulon Cytoscape App and candidate transcription factors 
were predicted [312]. Overrepresentation analysis (ORA) on DEGs lists was performed 
using the Functional Annotation Tool in DAVID website [313]. The lists of DEGs at 3 
and 24 h of estradiol treatment were used as input gene list and the mouse genome was 
used as background list. Biological processes, molecular functions and KEGG pathways 
were investigated focusing on enriched terms with a Benjamini adjusted p-value less 
than 0.05. A Protein-Protein Interaction Network of the differentially expressed genes 
has been created using STRING [280]. 
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3.7 Statistical analysis 
Unless otherwise stated, statistical significance was carried out with the GraphPad 
Prism version 5.02 for Windows by 1-way or 2-way ANOVA followed by Bonferroni 
post hoc test or unpaired t test; * p<0.05, ** p<0.01,  *** p<0.001 versus veh, and “n” 
indicates biological replicates. 
Based on studies previously conducted by our group, we assessed a "signal / noise" 
ratio of approximately 1.2. Establishing a significance level of 5% and a potency equal to 
80%, the minimum number of subjects for each experimental group more suitable to 
achieve the objectives of this project turns out to be greater than or equal to 12 [144]. For 
this reason we chose n=12 for icv experiments. 
Instead for zymosan (n=3), BrdU (n=4-6) and RNA-Seq (n=3) studies, we have not 
followed this rule, but we used fewer animals for each experimental groups, because 
they are initial and pilot experiments that need further experiments to improve 
statistical significance.  
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Most of the information about the effects of estrogen on macrophages in literature is 
related to the estrogen ability to modify their response to immunological stimuli, such 
as LPS or IL-4, and show that estrogen treatment is able to induce a more efficient 
inflammatory response in macrophages in these models. Then, to deeper understand 
the physiological response of macrophages to estrogen alone, in our laboratory was 
previously performed a study of genome-wide gene expression analysis of 
macrophages exposed to estrogen. Since our previous studies carried out in laboratory 
demonstrated that estrogen receptors (ERα and Gpr30) expression is decreased in 
primary macrophages cultures maintained in vitro compared to ex vivo macrophages,  
mouse in vivo treatment was chosen in order to better resemble physiological 
conditions. Because estrogens are endogenous hormones fluctuating during the estrous 
cycle, for this study we used female mice selected through the analysis of vaginal 
smears in  metaestrous (ME) phase, a phase of estrous cycle  with low endogen levels of 
estrogen. These animals were then injected with a physiological dose of 17β-estradiol 
(5μg/Kg). This approach provides an experimental asset to more faithfully mimic the 
mechanisms induced by the physiological estrogen surge in intact animals. 
Since macrophage activation is a dynamic process that leads macrophages to 
progressively adapt and modify their phenotype, we performed a time-course 
experiment, evaluating the effects on macrophage gene expression after short (3 hours) 
or long times (24 hours) from hormone treatment. 
Furthermore, female mice identified in estrous phase, which immediately follows 
endogenous hormone peak production, were used to evaluate estrogen physiological 
effect (Figure 1). 
 
 
 
 
 
 
 
Figure 1. Plasmatic estrogen levels in female mice. Figure modified from Della Torre et al., 2016 [281] 
17β-estradiol levels measured in the plasma of female mice during the estrous cycle, that in mice last four days. 
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Experimental groups and schematic representation of the study is shown in Figure 2. 
Briefly, following the peritoneal lavage, resident macrophages were isolated through 
magnetic immunosorting using antibody raised against cd11b loaded with magnetic 
beads. RNA was extracted from sorted macrophage cells and analyzed by RNA 
sequencing. 
 
 
 
 
 
 
 
 
 
 
Figure 2. Genome-wide gene expression analysis of estrogen action on resident peritoneal macrophages. Figure 
modified from Lavin et al., 2014 [282]  Schematic representation of experimental groups (A) and experimental design 
(B).  
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4.1 Bioinformatic analysis of macrophage genes modulated by estrogen 
Firstly I performed bioinformatics analyses of the results obtained from RNA 
sequencing experiment, in order to evaluate the biological relevance of estrogen action 
on macrophages. In particular I focused on the differentially expressed genes (DEGs) 
analysis between the following groups,: 
_ female at metestrous (ME) vs female at metestrous after 3 hours from E2 injection 
(ME_3hE2)  
_ female at metestrous (ME) vs female at metestrous after 24 hours from E2 injection  
(ME_24hE2)  
 
4.1.1 Differentially expressed genes (DEGs) in macrophages following E2 treatment 
Our data show that short and long term hormonal treatments significantly affect 
expression levels of 569 transcripts in total. In particular, as shown in Figure 3A 
estrogen regulates 238 genes following 3 hours of treatment; of these ones, 114 genes are 
up-regulated and 124 are down-regulated. Instead, 24h hormone treatment modulates 
the expression of 441 DEGs, 217 up-regulated and 224 down-regulated. Moreover, 110 
DEGs are regulated both 3 and 24 hours by estrogen treatment: 46 up-regulated, 63 
down-regulated and only one gene (Itgb3) with opposite trend between the two 
experimental comparisons. 
Heatmap in Figure 3B shows the graphical representation of the 569 differentially 
expressed genes in the 3 experimental groups: ME, ME_3hE2 and ME_24hE2. 
Grouping up- or down-regulated DEG according to onset and duration of hormone 
action, we identified different expression profile that we can cluster into 4 groups by 
their expression pattern across experimental groups: cluster I) includes the early and 
transient expressed genes, induced or inhibited only at 3h of E2 treatment; cluster II) 
includes early and persistent responsive genes, similarly modulated at 3 and 24h; 
cluster III) gathers early and progressively DEGs, regulated at 3 h and furthermore at 24 
h treatment; cluster VI)  includes late expressed genes, up- or down-regulated only at 
24h (Figure 3C). The differentially expressed genes (DEGs) list is shown in 
Supplementary Table 1. DEGs ranking is based on both their cluster belonging to and 
their estrogen responsiveness (LogFC). 
Analysis of clusters kinetics showed a significant fraction of DEGs (35%; clusters I+II) 
behaving as early responsive genes, since it’s already modulated at 3 h after E2 
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administration. Only a minor fraction of them returns to control levels after 24 h 
treatment (16%; cluster I), while the majority of all DEGs are modulated at this late time 
point (86%; clusters II+III+IV). Progressively responsive genes represent the highest 
number of regulated genes (37%; Cluster III), while genes regulated only at late time 
point constitute a high proportion of genes (28%; cluster IV) (Figure 1B).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Gene clustering by temporal expression profile in response to in vivo E2 administration. 
RNA sequencing analysis was performed on non-elicited peritoneal macrophages obtained from metaestrous (ME) 
female mice after in vivo treatment with vehicle (ME) or with E2 for 3h (3hE2) or 24 h (24hE2).  
(A) Venn diagrams representing the overlap and the number of macrophage DEGs regulated by E2 after 3 and 24 
hours of treatment. The number of up (red) and down (green)-regulated genes in each comparison are shown. (B) 
Heat map representing  the expression profile of DEGs in the 3 experimental groups (red, high relative expression; 
black, mean expression; green, low relative expression). (C) DEGs were grouped in 8 clusters, according to the net 
expression profile calculated by k-means clustering. The clusters with the same absolute trend among the 3 
experimental groups were merged. Relative expression levels for each gene in the different experimental groups are 
shown in relation to the mean expression values (magenta line). 
The number of genes  resulting in clusters a-d) are shown, together with the number of up (red) or down (green)-
regulated genes.  
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4.1.2 Bioinformatic transcriptional analysis of DEGs 
After I performed bioinformatic analysis to identify the main transcriptional factors 
involved in the regulation of DEGs expression in order to gain insight into the 
mechanisms of hormone responsiveness and individuate common regulatory networks. 
To analyze ER binding sites, I referred to database of  Bourdeau et al. [283] which 
identifies consensus EREs in mouse genome located up to approximately 10 kb from 
transcriptional start sites, through a genome-wide screening. Our data show cross-
interference among different clusters, as this regulatory element is enriched with similar 
frequency of DEGs enhancers/promoters in all fours clusters (Figure 1C and 
Supplemental Table 1). Thus, these analyses support the hypothesis that early and late 
effects induced by estrogen on macrophage transcriptome are mediated by direct ERE-
mediated mechanisms as well as by the ordered engagement of distinct sets of 
transcription factors that allow the specific temporal profile of gene regulation observed 
in response to estrogen. 
Then, a motif enrichment analysis was conducted to search for transcriptional 
regulatory elements in the promoters of macrophage DEGs. Each cluster includes 
unique transcription factors that are involved either in the up- or down-regulation 
effects, with up-regulated genes in cluster I showing a high abundance of binding sites 
for C/EBP transcription factors, an enrichment for E2f binding sites in cluster II, and for 
Irf and Stat families of transcription factors in cluster IV (Figure 1C). In parallel, specific 
transcriptional regulators are involved also in the down-regulation of DEGs in a cluster-
specific manner 
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Figure 4. Transcriptional analysis of macrophage DEGs promoters. 
A) Venn diagrams representing the number of macrophage DEGs with at least one estrogen responsive element 
(ERE) in their promoters in each comparison. The percentages of DEGs with ERE on total DEGs for each comparison 
are shown. B) Transcription factors (Txf) that bind putative binding sites in up (+) or down (-)-regulated genes are 
listed for each cluster; the column on the right shows the number of genes with Txf binding sites in their promoters 
reported as the percentage of the total number of up (+) or down (-)-regulated genes in each cluster. Esr1/2: binding 
sites for estrogen receptors  
 
 
 
 
Taken together, these data show that the in vivo administration of a physiological dose 
of E2 results in the regulation of expression of a distinct set of genes in macrophages, an 
effect which is evident shortly after hormone administration and progresses with time 
through a balanced combination of positive and negative distinct or overlapping 
pathways. 
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4.1.3 Biological pathways regulated by 17β-estradiol in resident macrophages 
In order to translate comprehensive genomic information into functional relevance, we 
performed functional annotation analyses using Gene Ontology term enrichment to 
search for significant terms related with biological programs. Enrichment of specific 
biologic categories (Supplemental Table 2) showed that, in analogy with gene 
expression, the time-course evaluation of estrogen action identifies biological programs 
that are either uniquely or commonly regulated as early or late responses to estrogen in 
macrophages (Figure 5A). Genes showing early and transient response to estrogen 
resulted enriched in specific gene ontologies including transcription factors, apoptosis, 
stress response, and protein folding, while the ontology related with lipid metabolism 
was enriched as a late responsive pathway. However, three functional programs clearly 
emerged as persistent estrogen-responsive pathways in macrophages: these relate with 
cell cycle, immune response, and wound healing. As shown in Figure 5B, a search for 
functional interactions using the String database resulted in a high number of 
connections among proteins encoded by genes involved in the Cell cycle, Immune 
response and Wound healing processes. The first category appears to be supported by 
the coordinated regulation of a core of highly interconnected genes, while the last two 
categories share a high number of proteins modulated by estrogen and are known to 
converge on the alternative polarization of macrophages (Figure 5B). Interestingly, 
some of the main transcription factors shown in Figure 1C are known to be involved in 
cell cycle progression, including C/EBPs, E2fs and Myc, or in the control of 
inflammation and macrophage polarization, including NF-kB, FOXP1 and Gabpa 16, 
further supporting the functional implications of estrogen action on macrophages and 
providing a first hint on the underlying molecular mechanisms. Altogether, these 
results show that estrogen induces in macrophages specific biological pathways related 
to distinct functional responses supported by an highly interconnected network of 
hormone-responsive genes (Figure 5B). 
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Figure 5. Biological pathways regulated by E2 in macrophages. 
A) The DEGs list from RNA sequencing analysis was submitted to the DAVID database for functional annotation. 
GO ontologies significantly modulated following 3 or 24 h of estrogen treatment are represented, with the number of 
genes regulated in each ontology reported as % of all regulated genes at each treatment. Immune response includes 
Immune response, Chemotaxis and Endocytosis; Wound healing includes Response to wounding, 
Hemopoietic/lymphoid organ development and Blood vessel development; Lipid metabolism includes Positive 
regulation of lipid metabolic process, Cholesterol metabolic process and Lipid localization. Ontology gene lists are 
reported in Supplementary Table 2. B) String diagram of the interactions among regulated genes. Genes of the Cell 
cycle (blue), Immune response (green) and Wound healing (red) are evidenced, with commonly regulated genes 
resulting in purple (Cell cycle + Immune response) and yellow (Immune response + Wound healing). The Venn 
diagram in the insert shows the numbers of unique or common regulated genes.  
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In conclusion, these analyses revealed that E2 modulates the expression of genes that 
are involved in biological processes in a dynamic manner, as some pathways are 
modulated earlier and others later in estrogen action. In particular, our data suggested 
that estrogen could induce macrophage proliferation as well as trigger a phenotypic 
adaptation of resident macrophages as a physiological response to hormone signal. 
 
 
4. 2 Estrogen is a physiological trigger of peritoneal macrophage cell cycle 
Cell replication and polarization consistently emerged as hormone-responsive 
programs and were thus selected for deeper investigation.  First we focused our 
attention on the study of the estrogen action on peritoneal macrophage proliferation. To 
this purpose, we performed a set of experiments to extend our observation by further 
modifying hormonal treatments and, more importantly, to evaluate the effects of 
changes in endogenous estrogen. 
 Thus, for this study, we carried out  a time course experiment, treating ME female 
animals with E2 for 3, 24 and 48 hours. Female mice at ME were used as control, instead 
females in estrous phase were added to evaluate peritoneal macrophages physiological 
response to the endogenous increase in estrogen levels.  
Peritoneal macrophages extracted from these experimental groups were analyzed to 
assess estrogen action on macrophage proliferation through gene expression analysis 
and BrdU incorporation and Ki67 protein expression. 
 
4.2.1 Cell cycle genes 
First, the expression of genes associated to active replication, such as Ki67 and Ube2c, 
and cell cycle, such as Ccnb2 and Cdk1 (G1/S phase) has been analyzed through 
RealTime-PCR semi-quantitative analysis. Ct values of genes analyzed are shown in 
Supplementary Table 3A and 3B and are referred to two different independent 
experiments. 
As shown in Figure 6, all these genes were induced by the exogenous treatment with 
estrogen, as early as 3 h after injection. Particularly, for all genes except Ki67, the 
highest induction was reached after 3 h of estrogen treatment and was followed by a 
substantial decrease at later time-points. Importantly, also the physiological increase in 
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endogenous sexual hormones is able to induce the expression of cell cycle and 
replication genes, as demonstrated by the significant increase in mRNA levels of these 
genes in estrous phase compared to metaestrous group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Validation of E2 target cell cycle genes in peritoneal macrophages in vivo. 
Peritoneal macrophages were isolated from female mice at the metaestrous phase (ME) of the estrous cycle treated 
with E2 for 3, 24 and 48 h. Females in the estrous phase (E) were also investigated. Real time PCR was performed to 
detect the mRNAs coding for genes related with cell cycle phases and active replication (CcnB2, Cdk1, Ube2c; Ki67). 
 Data sets for each gene were calculated using the 2-ddCt method with respect to the mean value of the control group 
(ME). Bars represent mean values ± SEM (n = 5-10). Student’s unpaired t-test, *p<0.05 ; **p<0.01; ***p<0.001 versus ME. 
 
4.2.2 Macrophage proliferation 
As previously described in the introduction, recently it has been demonstrated that 
peritoneal macrophages, in analogy with macrophages that reside in other tissues, such 
as brain or liver, are maintained by local self-renewal without the contribution of the 
infiltration and differentiation of circulating monocytes. Considering the strong effect of 
estrogen on macrophage cell cycle gene expression, we speculate that estrogen can act 
as a proliferative signal for resident peritoneal macrophages.  
So, in order to have more biological proof of the effect of estrogen on macrophage 
proliferation, we evaluate Ki67 protein expression and BrdU incorporation by FACS 
analyses of macrophages sorted from ME female mice untreated or treated with 
estrogen for 24 and 48 hours and female mice in E, as previously described. 
According with the results of gene expression, a significant increase in the fraction of 
Ki67+ peritoneal macrophages was obtained from animals treated with E2 (Figure 7A 
and B) and, more importantly, also in female mice at the estrous phase (Figure 7B). 
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Even more evident was the effect of E2 on DNA synthesis (Figure 7C and D), which we 
measured by BrdU incorporation. BrdU is a nucleotide that is incorporated in the DNA 
during cell replication; we injected BrdU in the peritoneum of mice 2h before their 
sacrifice and analyzed its presence in the nucleus of ex vivo sorted macrophages by 
FACS using an antibody raised against BrdU. E2 significantly increased the percentage 
of cells that were duplicating their DNA following 24 h of treatment. However BrdU 
incorporation was not increased in the other experimental groups, suggesting that the 
effect on DNA duplication was restricted to a specific time window of E2 action 
encompassing the first 24 h after treatment without being detected in the estrous phase 
or at a later time point (48 h; Figure 7D), when the increased number of cells 
progressing in the cell cycle (assessed by Ki67 expression in Fig. 7B) is probably too 
small to allow the detection of cells within the S-phase. Of note, the amplitude of 
estrogen action on BrdU incorporation is similar to that reported for IL-4, the most well-
characterized signal inducing local expansion of peritoneal macrophages in 
inflammatory conditions [174]. 
Moreover, these results lead us to hypothesize that the number of peritoneal 
macrophages is increased following estrogen treatment. To this purpose, number of 
macrophages extracted from the experimental groups previously described was 
assessed by evaluating the number of cd11b+ cells isolated from each sample through 
magnetic immunosorting. Figure 7E shows the percentage of cd11b+ cells on total 
number of cells isolated from peritoneum. As expected, the number of cd11b+ cells was 
significantly increased following 24 h of estrogen treatment and, more importantly, also 
in E phase (Figure 7E; Supplementary Table 4). However, there was no significant 
increase in the number of macrophages at the later time point (48 h), suggesting that in 
response to estrogen macrophages proliferate and subsequently undergo apoptosis or 
migrate in other tissues. 
These results clearly show that estrogen is a physiological trigger of macrophage 
proliferation, leading a 8% of cells to replicate and proliferate. 
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Figure 7. Estrogen induces macrophage proliferation. 
 (A-D), Proliferation was analyzed by evaluating Ki67 expression and BrdU incorporation by peritoneal macrophages 
from female mice at ME or 24 and 48 h after E2 treatment. Females in the estrus phase (E) were also analyzed. Mice 
were injected i.p. with BrdU 2 h prior to analysis. Representative dot plots depicting gating schemes for Ki67 and 
BrdU analysis are shown in panels A and C, respectively. Doublets were removed based on FL2 scatter width (FL2-
W)/FL2 scatter area (FL2-A). Bar charts show the percentage of Ki67 (B) and BrdU (D) positive macrophages. Data are 
representative of three independent experiments. Graphs represent the mean ± SEM of 4-9 mice per group. (E), Bar 
charts represent the percentage of cd11b+ cells isolated from the peritoneal lavage fluid. Results are expressed as the 
mean ± SEM (n=4-9). 
 Student’s unpaired t-test, *p < 0.05; °; **p<0.01; ***p<0.001 versus ME. 
. 
 
4.2.3 Ovariectomy affects macrophage population 
From these data we reasoned that, if estrogen is involved in peritoneal macrophage self-
renewal, we would expect that the number of peritoneal macrophages was reduced 
following estrogen deprivation. To this aim, we analyzed the number of macrophages 
in female mice that underwent ovariectomy, in order to eliminate the endogenous 
production of sex hormones. Cell peritoneal populations, in particular,  macrophages, 
neutrophils, monocytes and eosinophils, were analyzed by FACS analysis evaluating 
the expression of specific markers. Gating strategy is shown in Supplementary Figure 1. 
Our gene expression and flow cytometry data also confirmed that increased estrogen 
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levels do not change the expression of leukocyte markers such as CD11b and F4/80 
(Supplemental Table 1 and Supplemental Figure 2) 
As expected, ovx animals showed a significant reduction in the number of resident 
peritoneal macrophages as compared to sham-operated animals, and this effect  was 
completely reverted by estrogen replacement (Figure 8). While other leukocyte 
populations remained unchanged (Figure 8), indicating a specific action of estrogen on 
macrophage proliferation. 
Taken together, these observations demonstrate that estrogen acts as a proliferative 
signal for resident peritoneal macrophages 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Long-term exposure to exogenous E2 induces macrophage proliferation in ovx animal 
Ovariectomized female mice were treated with vehicle (ovx, black bars) or E2 (grey bars) for 60 h. Sham-operated 
mice treated with vehicle were used as controls (open bars). The peritoneal lavage fluid was analyzed by flow 
cytometry to evaluate the percentage of macrophages and other immune cells, as indicated. Results are expressed as 
the mean ± SEM (n=3). Student’s unpaired t-test, *p < 0.05 versus sham; °p < 0.05 versus ovx. 
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4.3 Estrogen is a physiological trigger of M2 peritoneal macrophage polarization 
In addition to the cell cycle ontology, our bioinformatics analyses suggested other 
ontologies to be responsive to estrogen: macrophage immune polarization and wound 
healing. These two functional categories are associated with the alternative polarization 
of macrophages, a process involved in the resolution of inflammation and in tissue 
repair.  
Thus, we performed a set of experiments, in order to deeper understand the effect of 
estrogen on macrophage alternative polarization. 
 
4.3.1 M2 macrophage polarization genes 
First, We evaluated the expression of genes involved in M2 polarization, such as Arg1 
Ym1 and Vegfa, following estrogen administration.  The expression of these genes has 
been analyzed, through RealTime-PCR semi-quantitative analysis, on peritoneal 
macrophages isolated from female mice at ME or following E2 treatments for 3, 24 and 
48 h and female in E, as previously described. Ct values of genes analyzed are shown in 
Supplementary Table 5A and 5B and are referred to two different independent 
experiments. 
As shown in Figure 9, estrogen significantly increases  the expression  of these genes 
already after 3 hours of estrogen treatment, where was reached the highest induction. 
Moreover, for all these genes the effect was still observed at extended time points. 
Remarkably, also the endogenous increase in estrogen levels, that is present in the 
females in the estrous phase, resulted in significant higher levels of the mRNA coding 
for Arg1 and Vegfα.  
These data suggested that estrogen was able to trigger a macrophage phenotype that 
resembled the alternative polarization induced by immune mediators, like IL-4.  
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Figure 9. Validation of E2 target M2 polarization genes in peritoneal macrophages in vivo. 
Peritoneal macrophages were isolated from female mice at the metaestrous phase (ME) of the estrous cycle treated 
with E2 for 3, 24 and 48 h. Females in the estrous phase (E) were also investigated. Real time PCR was performed to 
detect the mRNAs coding for genes related with M2 polarization (Arg1, Ym1, Vegfα). 
 Data sets for each gene were calculated using the 2-ddCt method with respect to the mean value of the vehicle group 
(ME). Bars represent mean values ± SEM (n = 5-10). Student’s unpaired t-test, *p<0.05 ; **p<0.01; ***p<0.001 versus ME. 
 
 
 
4.3.2 Macrophage phenotypic adaptation following E2 action 
It is known that the induction of one phenotypic state can change with time and 
progress towards distinct phenotypes that allows tissue remodeling and resolution of 
inflammation. We thus asked whether also estrogen was able to operate this phenotypic 
conversion.  
In order to evaluate macrophage polarization as a dynamic response to estrogen, 
ovariectomized mice were repeatedly administered with estrogen for prolonged 
periods of time (36 and 60 hours) and macrophages were sorted from the peritoneum. 
The expression of genes associated with  activation state were analyzed by RealTime-
PCR.  
As shown in Figure 10, ovariectomy did not alter the basal expression of Arg1, Tgm2, 
and Vegfα mRNAs. However, as expected, estrogen induced a phenotypic adaptation 
of macrophages, as demonstrated by the expression of selected M2 genes, such as Arg1, 
Tgm2 and Vegfa, that are significantly increased after 36 h and return to basal levels 
after 60 h E2 treatment, suggesting a reduced estrogen responsiveness at this late time 
point or a phenotypic transition of macrophages to the resolution phase. 
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In fact,  at this longer period of time, estrogen induced the expression of IL-10, a key 
mediator in the resolution phase of inflammation as shown by the significant increase in 
animals treated for 60 h with estrogen as compared to sham or ovx groups. 
Moreover, according to our previous data, a significant induction of Ki67 expression, 
was observed in estrogen treated animals. 
These results demonstrated that macrophage response to estrogen dynamically changes 
the expression programs to support the alternative polarization of resident 
macrophages and its progression towards a pro-resolution state. 
 
 
 
Figure 10. Estrogen long exposure induce macrophage phenotypic adaptation. 
Peritoneal lavage fluid was collected from sham-operated (not shown), ovariectomized (ovx, shown as time 0) or ovx 
mice treated with E2 for 36 or 60 h. Macrophages were immunosorted and analyzed by real time PCR for gene 
expression. Data show the expression levels of genes related with proliferation (Ki67, open circles), alternative 
activation (Arg1, filled squares; Tgm2, open squares) and wound healing (Vegfα, triangles; IL-10, filled circles). 
Values were calculated using the 2-ddCt method and normalized for the value of the sham group used as reference (=1) 
for each gene. Results are expressed as the mean ± SEM (n=3). Student’s unpaired t-test, *p<0.05 versus ovx. 
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4.3.3 Estrogen promotes macrophage alternative polarization in an in vivo model of self-
resolving inflammation 
In order to better understand the functional relevance of estrogen action on 
macrophage, we performed an experiment using an acute inflammatory animal model 
that is peritonitis induced by zymosan injection. 
Zymosan is a polysaccharide component of the yeast wall that induce activation of the 
immune cells, characterized by the activation of inflammatory response followed by the 
resolution of inflammation. The first phase of inflammation is driven by M1 
macrophage, mostly derived from monocyte recruitment following zymosan injection. 
The resolution phase, instead, is driven by the different subtypes of M2 macrophages 
that lead to tissue repair and restore homeostasis. 
For this experiment, we used ovariectomised animals to block estrogen endogenous 
production; these animals were treated with vehicle or E2 immediately before zymosan 
injection and after 24 and 48 h. Sham-operated animal were used as control. 
At different time points (12, 36 and 60 hours), we evaluated cell populations recruited in 
the peritoneum trough FACS analysis and extracted RNA specifically from sorted 
macrophages for gene expression analysis. Moreover, secreted factors involved in 
macrophage polarization, such as Tnfα (M1) and Vegfα and IL-10 (M2) was measured 
in peritoneal fluid of these experimental groups, through ELISA assay. 
Facs analyses in sham experimental group show the typical alteration of cell 
populations in zymosan animal model during the progression of inflammation, with 
reduction of macrophage number following their increasing in time to resolve 
inflammation (triangles, Figure 11C)  and, on the contrary, the increase of neutrophils 
(PMN) that decrease during disease. Gating strategy for the detection of the different 
peritoneal cell populations is shown in Supplementary Figure 1. 
The absence of estrogen didn’t affect the number of PMN, monocytes and macrophages 
(open cycle, Figure 11A, B and C). But, also in this model estrogen treatment increased 
the number of resident peritoneal macrophages following 60 h of estrogen 
administration. Moreover estrogen treatment didn’t affect the number of neutrophils 
and monocytes indicating a direct effect of estrogen on resident macrophages, not due 
to an increase of monocytes recruitment. 
Gene expression analysis clearly shows an effect of estrogen on M2 polarization (Figure 
11 E-H). In fact, estrogen potentiates Arg1 and Vegfa after 36 h treatment  and their 
expression is  reduced e after 60 h. In agreement with this anti-inflammatory effect of 
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estrogen, TNFα expression, an M1 gene,  is increased by hormone loss and strongly 
reduced by estrogen treatment. Moreover IL-10 expression is significantly higher in 
animals treated for 60 h with estrogen as compared to sham or ovx groups.  
Analysis of protein expression of Vegfα, IL-10 and TNFα in peritoneal fluid of 
experimental samples partially confirm gene expression results (Figure 11 H-L). In fact, 
even if Vegfa is not increased following estrogen treatment, maybe due to the high 
biological difference in the 3 replicates or to the sensibility of the assay, TNFα is 
significantly increased in ovx groups and reduced following estrogen treatment. 
According to gene expression, also IL-10 is increased by estrogen following 60 hours of 
treatment, although not in significantly way (Figure 11I, Supplementary Table 6A,B,C). 
These results demonstrated that during local inflammation estrogen dynamically with 
time induces programs to support an increase in number of resident macrophages and 
their alternative polarization to sustain the resolution phase, in agreement with our 
previous data. 
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Figure 11. Estrogen induces resident macrophage polarization. 
 (B-H) Sham-operated (triangles), ovariectomized (open circles), or ovariectomized and treated with E2 (filled circles) 
animals were injected with zymosan and the number of peritoneal macrophages, polymorphonuclear cells (PMN) 
and monocytes was analyzed by flow cytometry at different time points (panels B-D, respectively). Immunosorted 
macrophages were analyzed by real time PCR for the expression of genes, as indicated (panels E-H). Values of the 
sham group were used as reference (=1) and are not shown; ovx values are shown at time 0. Data were calculated 
using the 2-ddCt method and normalized for the value of the sham group for each gene. Results are expressed as the 
mean ± SEM (n=3). Student’s unpaired t-test, *p<0.05 versus ovx. 
(H-L) Protein concentration of Vegfα, IL10 and TNFα was evaluated in peritoneal fluid. 
Results are expressed as the mean ± SEM (n=3). Student’s unpaired t-test, **p<0.01 versus sham; ° p<0.05 versus ovx. 
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4.4 Molecular mechanism of estrogen action on macrophages 
We believed it was necessary to develop a model of macrophages in culture, in order to 
investigate the mechanism of estrogen action on macrophages and study in future the 
drug activity on this pathway. To this purpose, bone marrow derived macrophages 
(BMDMs) are a useful model that are a widely used and easy availability, although 
there may be some differences due to the in vitro system. We thus prepared primary 
cultures of BMDMs, treated with estrogen and analyzed target gene expression in 
comparison with peritoneal macrophages. Ct values obtained from RealTime PCR 
analysis are reported in Supplementary Table 7. 
As shown in Figure 12A, transcripts coding for Angtpl-4 and VEGFα, an ERE-positive 
genes (Supplementary Table 1), were modulated by increasing concentrations of 
estrogen in isolated macrophages. Interestingly, levels of transcript coding for Arg1, a 
cluster II gene with no ERE in its promoter/enhancer region, were also significantly 
increased by estrogen treatment, though the overall effect of estrogen was significantly 
lower. 
Since effect of estrogen in isolated macrophages was similar between the two different 
populations of macrophages and to that observed in vivo (Supplemental Table 1), we 
used primary cultures of BMDMs for further analysis, using ERα-KO animals and 
assessed whether the observed effects are dependent on this specific receptor . 
Ablation of ERα gene resulted in loss of estrogen action in macrophages, as estrogen-
induced changes in the mRNA levels coding for Vegfα, Angtpl4 and Arg1 observed in 
wild-type cells were not detected in ERα-KO macrophages (Figure 12B). 
These results demonstrate that estrogen may directly act on macrophages to modulate 
gene expression  and this effect is mediated by the activation of ERα signaling and 
allow further studies of SERMs activity on these cells. 
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Figure 12. Regulation of target gene expression by E2 in isolated macrophages. 
BMDM were grown in culture and assayed for gene expression following E2 administration. (A) BMDM cells were 
treated with vehicle (veh, open bars) or increasing concentrations of E2 (10-9, 10-7 and 10-5 M, filled bars) for 3 h. Real 
time PCR was used to analyze the mRNA levels coding for Vegfα, Angtpl4 and Arg1. (B) Comparison of estrogen 
action in BMDM cells from WT and ERα-KO (ERKO) mice. The mRNA levels coding for Vegfα, Angtpl4 and Arg1 
were analyzed 24 h after the addition of vehicle (veh, open bars) or 10-7 M E2 (filled bars). Data sets for each gene 
were calculated using the 2-ddCt method with respect to the mean value of the vehicle group. Bars represent mean 
values ± SEM (n=2). Student’s unpaired t-test, *p<0.05; **p<0.01 versus veh. 
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4.5 Microglia response to the estrogen surge 
Macrophages are widely distributed in almost all tissues of the body where they 
perform innate immune reactions; however, it has been shown that the 
microenvironment is also important for shaping macrophage metabolism and 
reactivity. Leading to resident macrophages with specific functions and responsiveness 
to signals. We thus were interested in extending our observations and evaluating the 
degree of conservation of estrogen signaling in different tissue resident macrophages. 
We chose microglia cells for our investigations, since some studies, also conducted in 
our laboratory, reported that these cells are responsive to estrogen which modifies cell 
activation leading to a reduced M1 in favor of an M2 activation state [223, 307]. 
Moreover, we also set up the experimental procedures to evaluate microglia M2 
polarization following IL4 injection (Pepe et al., 2014 [314]). Since microglia M1 
activation is a common feature of different neurodegenerative diseases and it 
contributes to tissue damage and neuronal death, induction of M2 microglia 
polarization by estrogen might counteract chronic inflammation and slow disease 
progression. However, the molecular targets of estrogen action in microglia are still 
poorly understood. In order to find biomarkers of estrogen action in microglia we thus 
decided to evaluate the microglia expression of some of the genes validated in my 
previous experiments in response to in vivo estrogen administration..  
To this purpose, female mice identified in ME were treated with physiological dose of 
E2 or veh for 24 h. Isolated microglia was analyzed for the gene expression of those 
genes regulated by the hormone, found trough genome wide analysis previously 
performed (Supplementary Table 1). Ct values obtained from RealTime PCR analysis 
are reported in Supplementary Table 8.  As shown in Figure 13, estrogen significantly 
induce the expression of some M2 markers, such as Fizz1 and Ym1, but no Vegfα and 
Tgm2. Instead, estrogen modulates Gas6 expression as well as in peritoneal 
macrophages (Supplemental Table 1).  Instead, no effect on cell cycle genes was 
observed in E2 treated samples. 
These data show that in response to E2 microglia acquire a M2-like phenotype, 
although inducing a different panel of M2 markers as compared to peripheral 
macrophages. However, differently to peritoneal macrophages, microglia are not able to 
proliferate in response to E2.  
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13. Validation of E2 target genes in microglia in vivo. 
Microglia was isolated from female mice at the metaestrous phase (ME) of the estrous cycle treated with E2 for  24 h. 
Real time PCR was performed to detect the mRNAs coding for genes related with (A) M2 polarization (Fizz1, Ym1, 
Vegfα, Gas6) and (B) cell cycle (Ccnb2 and Cdk1). 
 Data sets for each gene were calculated using the 2-ddCt method with respect to the mean value of the control group 
(ME). Bars represent mean values ± SEM (n = 2-5). Student’s unpaired t-test, *p<0.05 versus ME. 
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4.5.1 Microglia and macrophage response to IL-4 
Microglia local proliferation is a new concept  in neurology and neuroinflammation, 
however it has not yet been studied whether microglia is able to proliferate following 
stimulation with IL-4, the typical M2 activation signal, which  instead is known to 
induce the proliferation of peripheral macrophages, such as peritoneal cells [119, 130]. 
Since E2 previous results showed that microglia are not able to proliferate after E2 
treatment, differently from what happens for peritoneal macrophages, we tried to 
understand if  microglia was able to proliferate in response to another M2 signal. 
Thus, we evaluated proliferative response of microglia following IL-4, which is known 
to induce macrophage proliferation in the periphery. 
To this purpose, we used icv injection of IL-4, a model that we recently set up in our 
laboratory in order to study M2 microglia polarization in mice (Pepe et al. [314]). 
Our results show that IL-4 central injection is not able to induce cell cycle genes 
expression in the brain, while, as expected, IL-4 is able to induce macrophage 
proliferation in the peritoneum, as demonstrated by the significant increase in mRNAs 
coding for genes related to the cell cycle, such as Ccnb2, Cdk1 and Ki67 (Figure 14A). In 
microglia IL-4 is able to efficiently induce the M2 phenotype, as demonstrated by the 
increase in Arg1. (Ct values obtained from RealTime PCR analysis are reported in 
Supplementary Table 9). 
These results indicate that IL-4, the prototypical M2 signals, similarly to E2, is not 
associated with the proliferation of microglia cells, in contrast to its activity on 
peritoneal macrophages. 
Taken together these results demonstrate that estrogen has a different effect on 
microglia as compared to that exerted on peripheral macrophages (peritoneal 
macrophages and BMDMs) (Supplementary Table 1 and Figure 6,9,12), suggesting that 
microenvironment crucially affect macrophage responsiveness. 
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Figure 14. Regulation of cell cycle genes by IL-4 in peritoneal macrophages and brain microglia  in vivo. 
Animals were treated for 24h with IL-4 or veh through icv injection for brain analysis or i.p. for peritoneal 
macrophages analysis. Real time PCR was performed to detect the mRNAs coding for genes related with (A) cell 
cycle(Cdk1, Ccnb2 and Ki67) (B) M2 polarization (Arg1) in brain and peritoneal macrophages. 
Data sets for each gene were calculated using the 2-ddCt method with respect to the mean value of the vehicle group 
(ME). Bars represent mean values ± SEM (n = 2 for peritoneal macrophages, n = 12 for brain). Student’s unpaired t-
test, *p<0.05 ; **p<0.01; ***p<0.001 versus ME. 
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A combination of mechanisms, including direct genomic and epigenetic effects as well 
as interactions with transcription factors, co-regulators, cytoplasmic signaling pathways 
and intercellular communications, have been shown to support the effects of estrogen 
on the immune system [133, 284-285].  This integrated analysis of the in vivo response of 
macrophages to estrogen has revealed the existence of a physiological endocrine-
immune crosstalk that links estrogen action with proliferation of resident macrophages 
and their immunophenotypic adaptation, thus contributing relevant insights to our 
understanding of estrogen impacts on the regulation of the inflammatory response. The 
experimental conditions and transcriptomic approach adopted have led to a detailed 
temporal prospective of this endocrine-immune interplay and have identified a 
comprehensive list of molecular mediators involved. 
 The biological pathways most prominently modulated included macrophage 
proliferation, immune response, transcription factor expression, amino acid utilization, 
and energy metabolism, and on a whole indicated a key role for estrogen as a 
physiologic immunoregulatory factor for macrophage biology. Though the 
identification of the molecular mechanisms underlining the genomic events here 
reported require future investigation, our study reveals the identity and temporal 
responsiveness of a comprehensive set of novel estrogen-responsive genes 
(Supplemental Tables 1 and 2) that represent useful biological indicators of hormone 
signaling in macrophages. 
It has recently been demonstrated that peritoneal macrophages are maintained by local 
self-renewal, with a low level of proliferation throughout life regulated by growth 
factors and immune mediators including CSF-1 and IL-4 [114, 118-119, 286-288]. 
Functional annotation of DEGs suggested that estrogen also acts as a proliferative signal 
for resident macrophages. From a physiological point of view, our results provide a 
novel view of estrogen action in peritoneal homeostasis, in which macrophages are 
stimulated by estrogen to adapt and develop specific immune regulatory functions, 
possibly to cope with estrogen-induced changes in the environment. The nature of these 
concomitant events may include ovulation, with the need of increased macrophage 
number and activation in order to handle the wound healing response associated with 
follicle rupture and the induction of an immunotolerant environment which either 
favors egg fertilization and further implantation or eliminates dead cells and tissue 
debris resulting from luteal degradation. The advantage for estrogen to induce resident 
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macrophage proliferation instead of monocytes recruitment is unclear. As the estrogen 
surge occurs every 4-5 days in mice and it is perpetuated throughout the fertile life of 
females, it is possible that such circumstances direct the request of resident 
macrophages towards the expansion of local cells, a process that is energetically more 
favorable than the constant increase of hematopoietic precursors and their migration 
into the peritoneum [97]. Interestingly, our data also show that genes related with lipid 
metabolism are modulated by the hormone. Although not addressed in the present 
study, this evidence represents an additional indication of the metabolic adaptation of 
macrophages induced by estrogen which might serve the role of directing cholesterol 
and phospholipid metabolism towards the formation of membranes required for cell 
proliferation. 
Macrophage proliferation has been observed in selected murine and human tumors 
[289-290], including peritoneal neoplasia [291-292] and in Th2 inflammatory conditions 
[130], with variable involvement of IL-4 and CSF-1 depending on the specific 
experimental conditions [293]. Though a deep investigation of the underlying molecular 
mechanisms was precluded as estrogen proven to be unable to support macrophage 
proliferation in vitro, similar to what observed for IL-4, in our experimental conditions a 
significant induction of CSF-1 or IL-4 was not observed, arguing against the hypothesis 
that the estrogen effect is mediated by these mediators. Indirect mechanisms involving 
other peritoneal cells able to respond to the hormone cannot be excluded [284, 186], 
however we observed that EREs are present in the promoter of several cell cycle-related 
genes identified in the present study, including Chaf1a, CcnB2 and Wee1 [283], 
suggesting a direct binding of estrogen to the promoter of proliferation-related genes in 
macrophages. 
This study also provides the first demonstration that in vivo estrogen induces a 
phenotype resembling alternative macrophage activation that further converts towards 
a pro-resolving phenotype, as shown by changes induced by hormone replacement on 
polarization gene expression culminating with the induction of a key 
immunosuppressive cytokine typically expressed by macrophages during the 
resolution phase of inflammation, namely IL-10. Importantly, results obtained in the 
zymosan peritonitis model reveal that these mechanisms are maintained during an 
acute inflammation of the peritoneum. These results are in agreement with previous 
studies which suggested that estrogen is involved in macrophage activation and 
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polarization in experimental models of inflammation [191, 221, 294] or in isolated 
macrophages/cell lines challenged with specific immune stimuli [223, 295-296]. Our 
study provides a major advancement to this knowledge as it proves estrogen to be per 
se a physiological regulator of the number and reactivity of resident macrophages in 
intact healthy animals, in the absence of confounding factors such as recruited 
circulating monocytes achieved in wound healing or in different models of peritonitis. 
An abundant number of peritoneal macrophages showing a dysregulated polarization 
have also been involved in endometriosis, a pathological condition caused by the 
ectopic growth of endometrial cells in the peritoneum, [229, 297-298]. In particular, 
estrogen is known to drive detrimental effects on endometrial lesion development and 
progression through its well-recognized activity on endometrial cells [299-300]. 
Macrophages are involved in growth, sustainment and vascularization of endometriosis 
lesions, and their ability to switch from inflammatory to anti-inflammatory and 
resolving macrophages is altered in endometriosis [229, 301-302]. In this respect, the 
present description of the estrogen-macrophage signaling has intriguing implications 
for our understanding of endometriosis pathogenesis and therapeutic approaches, and 
candidate macrophage estrogen-responsive genes identified in this study as potential 
biomarkers in this clinical setting. Furthermore, the expression of the progesterone 
receptor is either absent or very limited in peritoneal macrophages, being below the 
detection limits in our assay. On the contrary, the progesterone receptor is highly 
expressed in endometrial cells and used as target of current therapeutic interventions 
for endometriosis that use progesterone analogues to block ER activity. The lack of 
progesterone receptor in peritoneal macrophages leaves estrogen action unopposed by 
progestin drugs in these immune cells, with possible reduction in therapeutic efficacy. 
Although the mechanisms provided in the present work suggest detrimental effect on 
certain pathologies, such as endometriosis, these events might be involved in the 
powerful suppressive influence exerted by estrogen in other inflammatory pathologies, 
such as those affecting the CNS or the lung  [303-304]. 
Several neurodegenerative diseases are associated with an  increased inflammation due 
to a chronic or unrestrained M1 activation of microglial cells that produce a wide array 
of chemokines, cytokines, reactive oxygen species that results in neurotoxicity. Together 
with activation, an increased proliferation of activated microglia has also been observed 
in association with acute CNS injury and chronic degenerative diseases. It is 
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hypothesized that dysregulated proliferation of microglia plays a detrimental role on 
neural cells in some neurodegenerative disorders such as Alzheimer’s disease and 
amyotrophic lateral sclerosis, as demonstrated by experimental approaches in which 
microglia proliferation has been blocked. Thus, targeting microglia proliferation may 
offer a new therapeutic strategy to selectively modulate disease outcome. On the other 
hand, an increased number of microglia with pro-resolving phenotype might have 
beneficial effects on disease progression; however, the ability of microglia to undergo 
alternative activation and proliferate in response to M2 signals in brain is not yet 
understood. In this scenario, our data showed that microglia, differently from 
peripheral macrophages, are not able to undergo proliferation in response to estrogen 
or IL-4,  although these signals are able to induce a M2-like phenotype. We do not know 
the explanation of this phenomenon, but we propose two hypothesis. The first one is 
that microglia express peculiar transcriptional regulators which are different from those 
expressed by peripheral macrophages and are engaged in the E2 response only in 
microglia cells. A second hypothesis envisions that  the different microenvironment 
signals instruct microglia to respond differently to M2 agents, causing proliferation to 
be dependent upon additional brain specific brain specific factors. 
Our results suggest that the modulation of estrogen signaling in macrophages might 
represent an important therapeutic strategy to develop new drugs for pathologies 
where estrogen-macrophage interplay may be crucial for disease development and 
progression, such as endometriosis, cancer and neurodegenerative diseases, and 
provide a list of E2 target genes that can be used as biomarkers for pharmacological and 
translational studies. This can lead to the design of more selective anti-inflammatory 
agents for pathologies characterized by chronic inflammation, such as 
neurodegenerative diseases, that, instead  to act only blocking inflammatory response, 
improve the resolution phase of inflammation, or to develop of selective modulators of 
estrogen signaling to limit M2 macrophage deleterious effects in pathologies like 
endometriosis and tumors. 
In conclusion, this study represents a key advancement for the understanding of the 
impact of estrogen on macrophage physiology and identifies novel mechanisms and 
underlying molecular players of potential pathophysiological relevance. 
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Future goals will be to deeper study the mechanisms activated by ERs, by which 
estrogen modulate macrophage physiology, particularly proliferation and polarization, 
for example the activation of PI3K/Akt signaling or Gpr30 involvement, in order to 
identify novel drug targets and leading to the design of more selective anti-
inflammatory agents. In light of the wide use of estrogenic drugs in therapeutic settings, 
it will also be interesting to understand the pharmacological activity of SERMs in 
macrophages, that is, whether these molecules act as agonists or antagonists of estrogen 
receptors, leading to predict a modulatory activity on inflammation also for this drugs. 
It will also be interesting to translate the data obtained in human pathology and study 
estrogen role in pathologies in which macrophage proliferation and polarization 
participate to disease progression, such as endometriosis and tumor.
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Supplementary Table 1. Differentially regulated genes (DEGs) in macrophages  following 3 and 24 h of estrogen 
administration to metaestrous female mice are listed according to lgFC; cluster and ontologies  associations and the 
number of ERE in the promoter/enhancer are reported. 
 
 
GENE 
logFC Cluster ERE Ontologies 
3h 24h 
   
                      
Vegfa
*
 3.22   I 1 IR; WH; TX; AP 
H2-M3 1.97   I   IR 
Lbx2
§
 1.80   I   TX 
Rpl39l
* 
1.56   I     
Hgd 1.53   I     
Fam187b
*
 1.47   I     
Prelid2
* 
1.43   I     
Ubxn6
*
 1.41   I     
Gsg1
* 
1.40   I     
Cdk1 1.39   I   CC; SR 
Ofcc1
* 
1.32   I     
Rad51ap1
§ 
1.27   I   SR 
Ckap2l 1.22   I     
Kif22 1.18   I   SR 
Oaf
* 
1.17   I     
Mxd3
* 
1.16   I   TX 
Itga7
* 
1.15   I     
Spc25
* 
1.15   I   CC 
Cd46
* 
1.13   I     
Trappc1
§ 
1.13   I     
Egr3 1.12   I   TX 
Cenph
*
 1.09   I   CC 
Depdc1b
* 
1.08   I     
Il1b
* 
1.08   I   IR; WH; LM 
Plekhf1
* 
1.07   I   AP 
Chaf1b
* 
1.07   I   CC; TX; SR 
Cdca5
§
 1.06   I   CC 
Pole
*
 1.04   I 1 SR 
Lpl 1.03   I 3   
Tgfbr3 1.03   I   WH; TX 
Fam101b
§
 1.01   I     
Cdca7 0.99   I   TX 
Sox7 0.97   I 1 TX 
Gmnn 0.95   I   CC 
Plod3 0.95   I     
Asf1b 0.90   I   TX 
Cxcr7 0.83   I     
Lonrf3 0.83   I     
Loxl2 0.81   I     
Nlrp3 0.79   I   IR; WH; TX; AP 
Tipin 0.76   I   SR; CC 
Nr4a1 0.76   I 1 TX; AP 
Hes1 0.71   I   TX 
Tacc3 0.70   I   CC; WH 
Itgb3 0.69 -0.63 I     
Fabp7 0.67   I 1   
Slpi 0.65   I 1   
Cdkn1a 0.63   I 1 CC; AP; SR 
Id2 0.63   I   WH; TX 
Klf4 0.62   I   TX 
Rab27a 0.52   I   IR; WH; AP 
Lrrk2 0.51   I     
Cdc42ep4 0.47   I 1   
Ccr2 0.44   I   IR; WH 
Fhit
*
 -2.17   I     
Ccl5 -2.14   I   IR; WH 
Ms4a4b -2.12   I     
Il7r
* 
-1.89   I 1 IR; WH 
Cldn20
§ 
-1.59   I     
Lat
*
 -1.56   I   IR; WH 
Il2rb -1.45   I 2 AP 
Slc18a2
§
 -1.43   I     
Mylpf
* 
-1.42   I 2   
Gm20735
* 
-1.36   I     
Serpine1
* 
-1.27   I 1   
Dnajb13
§ 
-1.24   I   PF 
Oas1g
* 
-1.24   I   IR 
Gm14393
§ 
-1.17   I     
Dhrs13
*
 -1.16   I     
Sec16b -1.15   I     
Bri3
* 
-1.13   I     
Per1 -1.13   I 1 TX 
Ifitm1
§
 -1.10   I     
Tcf7 -1.09   I 1 TX; AP 
Ly6c, Ly6i
* 
-1.09   I 1   
Lck
* 
-1.04   I     
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Tmem220
* 
-1.02   I     
Cyp11a1
§ 
-1.01   I     
Lyve1 -0.81   I     
Usp18 -0.80   I     
Dnajb1 -0.68   I   PF 
Per3 -0.63   I   TX 
Tbc1d9 -0.61   I     
Ccr7 -0.57   I   IR 
Frmd4b -0.57   I     
Ltb -0.51   I 1 IR; WH; AP 
Pou2f1 -0.49   I   TX 
Manf -0.47   I     
March1 -0.44   I     
Chaf1a
** 
1.55 1.34 II 1 CC; TX; SR 
S100a5
§,**
 1.37 1.45 II 1   
Zfp580
*,**
 1.32 1.03 II   TX 
Bub1b 1.3 1.38 II   CC 
Prc1 1.22 1.23 II   CC 
Cx3cr1
§,** 
1.20 1.13 II 1 IR; AP 
Ccr6 1.16 1.29 II     
Cenpk
*,** 
1.14 1.20 II   TX 
Nusap1 1.08 1.19 II   CC 
Serpinb2 1.03 1.00 II     
Ube2c
*,** 
1.00 1.07 II   CC 
Fam217b 0.95 0.95 II     
Slc16a3 0.92 0.59 II     
Ldlr 0.82 0.47 II   IR; LM 
Mcm5 0.82 0.78 II   TX 
Uhrf1 0.77 0.81 II   CC; TX; SR 
Lig1 0.76 0.83 II   CC; SR 
Ptgir 0.74 0.50 II     
Hk2 0.72 0.60 II     
Incenp 0.67 0.60 II 2 CC 
Mapk6 0.64 0.51 II   CC 
Adam8 0.63 0.61 II     
E2f3 0.60 <0.4 II   CC; TX 
Bcl3 0.60 <0.4 II   
IR; WH; TX; AP; 
SR 
Fam171a1 0.59 <0.4 II     
Slc9a9 0.59 <0.4 II     
Cd40 0.58 <0.4 II     
Cdkn2d 0.57 <0.4 II   CC 
Arf2 0.57 0.45 II     
Dram1 0.57 <0.4 II     
Ripk3 0.56 0.57 II   AP 
Kremen1 0.54 <0.4 II     
Abcg1 0.54 <0.4 II 1 LM; TX 
Padi4 0.53 <0.4 II 1 TX 
5430435G22Rik/Rab7b 0.51 <0.4 II     
Arhgef10l 0.50 <0.4 II     
Steap3 0.49 0.57 II   CC 
Plscr1 0.46 <0.4 II 1 WH 
B430306N03Rik/Treml6 0.45 0.46 II 2   
Dmpk 0.44 <0.4 II     
Mcm2 <0.4 0.53 II   CC 
Mrgprb2
*,** 
-5.04 -2.44 II     
Cpa3
*,**,^ 
-4.57 -1.90 II     
Mcpt4
*,**,^ 
-3.91 -1.65 II     
Cma1
*,**,  ^
-3.80 -1.87 II     
Tpsb2
*,**,^
 -3.72 -1.83 II     
Mrgprb1
*,** 
-3.57 -1.21 II     
Kit
*,**,^ 
-2.90 -1.43 II 2   
Angptl4 -2.76 -1.51 II 2 LM; AP; SR 
Slc6a4
*,** 
-2.50 -2.32 II 1   
Pdk4 -2.13 -2.46 II 2   
Ly6k -1.86 -1.74 II     
Cxcr4 -1.32 -0.83 II   WH 
Hsph1 -1.29 -1.28 II   PF 
Wee1 -1.23 -1.13 II 2 CC 
Dgke -1.10 -0.74 II     
Mbd1 -1.04 -1.09 II 1 TX 
Jdp2 -0.96 -0.48° II   TX 
Klf9 -0.92 -0.65 II   TX 
Fam46c -0.91 -0.74° II     
Gas5,Mir5117 -0.90 -0.95 II     
Per2 -0.85 -0.81 II 2 TX 
Stip1 -0.77 -0.58 II 1   
Cpt1a -0.77 -0.56 II     
Cep85 -0.77 -0.91 II     
Pik3r5 -0.76 -0.79 II     
Hsp90aa1 -0.74 <0.4 II   PF 
Ddit4 -0.74 -0.62 II     
Pgm2l1 -0.73 -0.55 II     
Herpud1 -0.72 -0.56 II 1   
Trim65 -0.70 <0.4 II     
Sfn -0.69 <0.4 II     
Sik1 -0.68 -0.54 II   CC 
Dnaja1 -0.68 -0.62 II 1 PF 
Cacna1e -0.68 <0.4 II     
Mll1 -0.67 -0.60 II   WH; TX 
Tagap -0.67 -0.56 II     
Oas2 -0.66 <0.4 II   IR 
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Trim47 -0.66 -0.73 II     
Stxbp3a -0.66 -0.71 II     
Trim7 -0.63 -0.56° II     
Nr1d2 -0.62 <0.4 II   TX 
Erdr1 -0.60 -0.50 II     
Tef -0.60 <0.4 II   TX 
Ino80d -0.60 -0.54 II     
Rusc2 -0.59 -0.66 II     
Slc37a2 -0.59 -0.54 II     
Jmy -0.58 <0.4 II   CC; TX; AP; SR 
Rnf169 -0.57 <0.4 II     
Fkbp4 -0.56 <0.4 II 1   
Tsc22d3 -0.56 <0.4 II   TX; AP 
Atxn1 -0.56 <0.4 II   TX 
Lmo7 -0.51 <0.4 II     
Tfb2m -0.51 <0.4 II   TX 
Rabgap1l -0.51 <0.4 II     
Ctns -0.51 -0.53 II 1   
Phf15 -0.50 <0.4 II     
Epas1 -0.50 -0.56 II 1 WH; TX; SR 
Mlxip -0.50 -0.44 II   TX 
Slc16a10 -0.48 <0.4 II     
Ypel2 -0.47 -0.49 II     
Ptpn22 -0.46 <0.4 II   WH 
Cacybp -0.45 <0.4 II 1   
Ubfd1 -0.44 <0.4 II     
Glcci1 -0.44 -0.5 II 1   
Il16 -0.43 <0.4 II 1 IR; TX 
Rc3h1 -0.43 <0.4 II     
Ahsa1 -0.43 <0.4 II   PF 
Crebbp <0.4 -0.5 II     
Diras2 <0.4 -0.41 II     
Bex6
** 
  4.46 III     
Spp1
*,** 
1.51 3.96 III   AP 
Arg1 0.81 2.81 III   WH 
Trem1
* 
1.72 2.09 III 2   
Nuf2
*,**
 1.41 1.86 III   CC 
Birc5
* 
1.26 1.78 III   CC; AP 
Ccnb2 1.38 1.76 III 1 CC; WH 
Kifc1   1.72 III   CC 
Gins2
§
 1.34 1.71 III     
Spc24
§ 
1.09 1.70 III   CC 
Fignl1
* 
1.18 1.47 III 1   
Ccnb1   1.45 III   CC 
Ccnf   1.45 III   CC 
Top2a 1.14 1.43 III 1 TX 
Mcm10
*,** 
1.07 1.41 III     
Camkk1   1.40 III 1   
Gm16907
** 
  1.39 III     
Cdca3   1.36 III   CC 
Mag
§§
   1.35 III     
Kif11   1.29 III   CC 
Rn45s 0.59 1.26 III     
Slc35g2
§§ 
  1.25 III     
Mki67 0.94 1.24 III   CC 
Stmn1 0.89 1.24 III   CC 
Timeless
** 
  1.19 III 1 CC 
Tpx2   1.16 III   CC 
Fxn
§§ 
  1.15 III     
Slc7a8 0.85 1.13 III     
Smim5
§§ 
  1.09 III     
Gm10814
** 
  1.08 III     
Dtl
**
   1.07 III     
Mefv
§§
   1.07 III   WH 
Cdc6
*
   1.04 III   CC 
Ccr5 0.5 1.02 III   IR; WH 
Kif23   1.02 III     
Syce2
** 
  1.01 III   CC 
Echdc3
** 
  1.01 III     
Lair1 0.54 0.99 III     
Dnajb5   0.98 III 1   
Rrm2   0.95 III 2   
Tgm2   0.94 III 1 WH 
Slfn9   0.94 III     
Marco 0.46 0.93 III 1   
Fcgr4 0.45 0.91 III     
Tgm1   0.91 III 1   
Aurkb   0.86 III   CC 
Arhgap19   0.86 III     
Emp1   0.86 III     
Layn   0.83 III     
Idi1   0.82 III   LM 
Guca1a   0.79 III 1   
Stxbp1   0.78 III 1 IR 
Cd300lf   0.78 III   IR 
Dab2   0.77 III 1 IR 
Il21r   0.77 III     
Ckb   0.76 III     
Cwc27   0.74 III     
Gm6682   0.74 III     
Dusp16   0.73 III     
Arl4c   0.70 III     
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Srxn1   0.67 III     
Dhcr24   0.65 III 2 LM 
Sel1l3   0.65 III     
Kpna2   0.64 III 1   
Kank2 0.51 0.64 III     
Msr1   0.62 III   IR; LM 
Fcrl5   0.62 III     
Pgk1   0.61 III     
Fmnl3   0.60 III     
Dpysl3   0.60 III     
Pkm   0.60 III     
Lbp   0.60 III   IR; WH; LM 
Cd300ld   0.59 III   IR 
Jam2   0.59 III     
Pla2g4a   0.58 III 1   
Fus   0.57 III     
Fgr   0.57 III     
C1ra   0.57 III   IR; WH 
Cd22   0.56 III 1   
Phyh   0.56 III     
Pdk1   0.56 III     
Rfx5   0.54 III     
Rhoh   0.53 III     
Lars   0.53 III     
Tlr1   0.51 III 1 IR; WH 
Nin   0.50 III     
Itga9   0.50 III 1   
Ifi30,Pik3r2   0.50 III     
Lrrc25   0.49 III     
Myo1e   0.49 III   WH 
Rhoc   0.47 III     
Impdh1   0.46 III     
Tpi1   0.46 III     
Ap2m1   0.46 III 1   
Ldha   0.45 III     
Jarid2   0.44 III     
Serpine2   -2.66 III 1   
Rasl10a
*,** 
-1.19 -2.55 III     
Gm16701   -2.44 III     
Fkbp5 -1.35 -2.37 III 2 PF 
Zbtb16 -1.09 -2.32 III   WH; TX; AP 
Hspb1 -1.33 -2.29 III     
Slc15a2   -2.19 III     
Klf15
*,** 
-1.34 -2.05 III   TX 
Tcf23
** 
  -1.91 III     
Zfp811 -0.87 -1.89 III   TX 
Rfx2 -0.55 -1.64 III   TX 
Tppp -0.51 -1.61 III     
Cyp26a1 -0.96 -1.58 III     
Plekha6 -0.56 -1.54 III     
Gpr114
** 
  -1.53 III     
Serf1
** 
  -1.50 III 1   
Map3k6 -0.72 -1.49 III 1   
Shank3   -1.46 III 1   
Ralgds -0.74 -1.45 III     
Lims2   -1.44 III     
Prtg   -1.39 III     
Krt7   -1.36 III   CC 
Eps8l1   -1.35 III     
Apoc1 -0.54 -1.29 III   LM 
Fam222a
** 
  -1.28 III     
Thbd -0.6 -1.26 III   WH 
Ryr2   -1.24 III     
Tacc2   -1.18 III   CC 
Klf11 -0.68 -1.18 III   WH; TX 
Fcer1a
^ 
  -1.17 III     
Tmem150b
** 
  -1.12 III     
Il6
** 
  -1.10 III   WH 
Orm2,Orm3
§§ 
  -1.09 III   WH 
Plin2 -0.78 -1.05 III   LM 
Il1rl1 -0.64 -1.05 III 2 IR 
Ccdc15
§§ 
  -1.04 III     
Frat2   -1.01 III     
Slc10a6   -0.98 III     
Tnfsf8   -0.93 III   IR 
Tnfrsf8   -0.92 III     
Cpm   -0.92 III     
Ier3   -0.91 III     
Cd93 -0.53 -0.90 III     
Ccm2l   -0.89 III     
Banp -0.64 -0.89 III   CC 
Stxbp3b   -0.88 III     
Sgms1 -0.6 -0.84 III   WH; AP 
Rai14   -0.84 III     
Glul   -0.80 III     
Hilpda   -0.80 III     
Sult1a1   -0.78 III     
Engase -0.5 -0.77 III     
Hist1h2bc   -0.76 III     
Nfkbiz   -0.76 III   WH 
Zfp97   -0.75 III     
Elovl5   -0.75 III     
 
 
120 
 
Mst1r   -0.73 III 2   
Snta1   -0.73 III 1   
Nrip1   -0.71 III 1 LM 
Irf2bp2   -0.71 III     
Zkscan3   -0.69 III     
Mdm1   -0.69 III     
Cdan1   -0.69 III     
Tns1   -0.68 III     
Epha2   -0.68 III 1 WH 
Igf1r   -0.68 III     
Dusp6   -0.68 III     
Slc27a1   -0.67 III 1 LM 
Prkar2b -0.49 -0.66 III 1   
Snhg11   -0.66 III     
Chordc1   -0.66 III 1   
Dapk1   -0.64 III     
Dhrs3   -0.63 III     
Wdr45   -0.62 III     
Cd300a   -0.62 III   IR 
Sh3bgrl2   -0.61 III     
Ulk1   -0.61 III 1 IR 
Notch1   -0.61 III   WH 
Edil3   -0.60 III     
Zbtb44   -0.58 III     
Mrvi1   -0.57 III     
Zfp36l1   -0.57 III 1 WH 
Cds2   -0.56 III     
Klhl24   -0.56 III     
Cnst   -0.55 III     
Dennd4c   -0.55 III     
Efcab4a,Pnpla2   -0.55 III     
Dnase1l2,E4f1   -0.55 III   CC 
Net1   -0.54 III     
2210018M11Rik/Emsy   -0.53 III     
Sorbs3   -0.53 III     
Pcmtd2   -0.53 III     
Ppl   -0.52 III 2   
Hspa12a   -0.51 III     
Arrdc3   -0.51 III     
Zmiz1   -0.51 III   WH 
Fam20c   -0.51 III     
Fam46a   -0.50 III     
Mob3b   -0.50 III     
Pgap1   -0.49 III     
Rfwd2   -0.48 III     
Ubn2   -0.48 III     
Bach1   -0.48 III     
Ube2h   -0.48 III     
Jag1   -0.47 III 1   
Wnt2   -0.47 III   WH 
Clec10a   -0.47 III     
Pnpla7   -0.46 III     
Dapp1   -0.46 III     
Pan3   -0.46 III     
Rassf3   -0.45 III     
Heca   -0.44 III     
Slc25a37   -0.43 III     
Zscan26   -0.43 III     
Dusp11   -0.42 III     
Ccl12
** 
  4.10 IV   IR; WH 
Upp1
** 
  3.30 IV     
Rab3il1   2.31 IV     
Chi3l3   2.16 IV 1 WH 
AA467197/Nmes1
** 
  2.05 IV     
Vcan   2.00 IV     
3110057O12Rik/Abhd18   1.95 IV     
Rarres2
§§ 
  1.75 IV     
Gas6   1.68 IV 1   
Ckap2
** 
  1.67 IV   CC 
Vpreb3
** 
  1.66 IV 2   
Siglec1   1.60 IV     
Aif1   1.55 IV 2   
Ccl22
** 
  1.53 IV   IR; WH 
Gm9920
§§ 
  1.50 IV     
Ucp1
§§ 
  1.40 IV     
Isg15   1.37 IV 1   
Chst11   1.37 IV     
Lars2   1.36 IV     
Rnf128   1.33 IV     
Eme1
** 
  1.32 IV     
Ifit3   1.31 IV     
Nxpe5   1.29 IV     
Il2ra   1.27 IV     
Cmss1   1.23 IV     
Fdps   1.19 IV 2 LM 
Fcgr1   1.17 IV   IR; WH 
Sfxn5   1.13 IV     
Papss2   1.12 IV   WH 
Trem2   1.09 IV     
Ngfr   1.08 IV   WH 
Gatm
§§ 
  1.04 IV   WH 
Rsad2   1.03 IV   IR 
 
 
121 
 
Soat2   0.97 IV   LM 
Mvb12b   0.95 IV     
Nme4   0.95 IV     
Tmem8   0.95 IV 1   
Fam213b   0.94 IV     
P2ry6   0.94 IV     
Folr2   0.93 IV     
Irf7   0.87 IV   IR 
Cbr2   0.86 IV     
Ifi27l2a   0.86 IV     
Slfn1   0.85 IV 1 CC 
Cplx2   0.85 IV   IR 
Ms4a6c   0.83 IV     
Mlkl   0.82 IV     
Ppapdc1b   0.82 IV     
Adap2   0.80 IV     
Galk1   0.77 IV     
Glrx   0.76 IV     
H2-Eb2   0.76 IV   IR 
Marcksl1   0.76 IV     
Zbp1   0.75 IV     
Nrp1   0.74 IV   WH 
Fpr2   0.72 IV   IR 
Oas3   0.72 IV   IR 
Cpne2   0.71 IV     
Pram1   0.70 IV     
Cd163   0.68 IV   WH 
Pam   0.68 IV     
Nlrc3   0.67 IV     
Ms4a6d   0.66 IV     
Dhx58   0.64 IV   IR 
Ddx60   0.64 IV     
Fcrl1   0.63 IV     
Epb4.1l1   0.62 IV     
Tnfrsf11a   0.61 IV     
Rbm3   0.61 IV     
Dhx29   0.57 IV     
Pik3ap1   0.56 IV     
Rhobtb1   0.55 IV     
Slfn5   0.55 IV     
Ctsc   0.54 IV     
Ckap4   0.54 IV     
Acp2   0.53 IV 2   
Lpin2   0.52 IV     
Plcb1   0.52 IV     
Dck   0.52 IV     
Atrip,Trex1   0.52 IV     
Tpcn2   0.52 IV     
Lgals1   0.51 IV 3   
Lman1   0.49 IV     
Lrrc59   0.49 IV     
F13a1   0.49 IV   WH 
Mrc1   0.49 IV   IR 
Etv5   0.49 IV 1   
Rtp4   0.48 IV     
Icam1   0.48 IV 1 IR 
Cd38   0.46 IV     
Nme1   0.46 IV   IR 
Ncbp1   0.45 IV     
Stat1   0.45 IV     
Ostc   0.44 IV     
Rgs1   -2.44 IV     
Mylk3
§§ 
  -1.88 IV     
Abca6   -1.84 IV 1   
Spa17
** 
  -1.72 IV     
Hhipl1   -1.71 IV     
Ccl3   -1.66 IV   IR; WH 
Nupr1l
§§ 
  -1.66 IV     
Dusp1   -1.49 IV   CC 
Fos   -1.34 IV     
Xlr3b
** 
  -1.26 IV     
Nr1d1   -1.19 IV 2   
Rab44   -1.15 IV     
Gm15471
** 
  -1.15 IV     
Cxcl2   -1.1 IV 2 IR; WH 
Cables1   -1.07 IV   CC 
Hgf   -1.03 IV 1   
Gfod1   -1.01 IV     
Art3
** 
  -1.01 IV     
Zfp72
** 
  -1.00 IV     
Egr1   -1.00 IV 1   
Tppp3   -0.99 IV     
Adamtsl4   -0.95 IV     
Fosb   -0.93 IV 1   
Nt5e   -0.91 IV     
Zfp36   -0.87 IV 2 WH 
Ccrl2   -0.87 IV     
Tox2   -0.86 IV     
Rgs2   -0.85 IV    CC 
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Ppap2a   -0.84 IV 1   
Cyp2ab1   -0.84 IV     
Insr   -0.81 IV     
Nedd4   -0.79 IV     
Tmem62   -0.76 IV     
Aqp9   -0.75 IV     
Hr   -0.74 IV 1   
Fabp4   -0.72 IV     
Jun   -0.69 IV     
Garnl3   -0.65 IV     
Ocln   -0.65 IV     
Abca9   -0.64 IV     
Rbpms   -0.62 IV     
Cd14   -0.60 IV 2 IR; WH 
Fgfr1   -0.60 IV   WH 
Hist1h1c   -0.60 IV     
Slc22a17   -0.60 IV     
Tln2   -0.60 IV     
Cav1   -0.58 IV   IR; WH; LM 
Plcb4   -0.58 IV     
Nfia   -0.57 IV     
Egln3   -0.57 IV     
Ston2   -0.56 IV   IR 
Tgfb2   -0.53 IV 2 IR; WH 
Calcoco1   -0.52 IV     
Myadm   -0.51 IV     
Pi16   -0.51 IV     
Icam2   -0.50 IV 1   
Gata6   -0.50 IV 1   
Csf3r   -0.50 IV   IR 
Cask   -0.47 IV 1   
Lama3   -0.46 IV     
Parvb   -0.46 IV     
Fcrls   -0.46 IV     
Slc9a3r2   -0.46 IV     
Junb   -0.45 IV   WH 
Mgst1   -0.43 IV     
 
 
 
AP, apoptosis; CC, cell cycle; IR, immune response; LM, lipid metabolism; PF, protein folding; SR, stress response; 
TX, transcription factors; WH, wound healing. *DEGS excluding anomalous value at 3h, * *DEGS excluding 
anomalous value at 24h; § DEGS with FPKM < 2 and >1 at 3h;  §§ DEGS with FPKM < 2 and >1 at 24h;  ^ genes 
excluded from GO analysis; ° not a DEG value. 
 
 
 
Supplementary Table 2 . Functional annotation analysis on the differentially expressed genes (DEGs) lists from 3 
and 24 h estrogen treatment was performed using Gene Ontology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes in bold, up-regulated genes; genes in normal typing, down- regulated genes. Cognate biological categories are 
grouped as: cell cycle (CC); immune response (IR); wound healing (WH); lipid metabolism (LM); transcription factors 
(TX); apoptosis (AP); protein folding (PF); stress response (SR). P-value <0.05. 
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Supplementary Table 3. Cell cycle genes expression. Ct values and 2-ddCt calculation. 
Peritoneal macrophages were isolated from female mice at the metaestrous phase (ME) of the estrous cycle treated 
with E2 for 3, 24 and 48 h. Females in the estrous phase (E) were also investigated. Real time PCR of two independent 
experiment (A and B) was performed to detect the mRNAs coding for genes related with cell cycle phases and active 
replication (CcnB2, Cdk1, Ube2c; Ki67). 
 Gene expression was normalized on 36B4 expression and data sets for each gene were calculated using the 2-ddCt 
method with respect to the mean value of the control group (ME).  
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Supplementary Table 4. % of cd11b+ peritoneal cells isolated from peritoneal lavage. 
Peritoneal macrophages were isolated from female mice at the metaestrous phase (ME) of the estrous cycle treated 
with E2 for  24 and 48 h. Females in the estrous phase (E) were also investigated. 
The number of cd11b+ cells isolated from each sample through magnetic immunosorting was calculated as % on the 
total number isolated from peritoneum. 
 
  Peritoneal Cells  Peritoneal Cd11b+ Cells 
Experimental 
group  
Sample 
Cells/ml      
(x106) 
Tot                   
(x3ml) 
Cells/ml      (x106) % 
ME 
6.2 1.93 5.79 1.67 28.84 
6.3 1.37 4.11 1.53 37.23 
6.4 3.33 9.99 2.41 24.12 
1.1 2.18 6.54 1.94 29.66 
1.2 0.99 2.97 0.66 22.22 
1.3 1.26 3.78 0.85 22.49 
  MEDIA       27.43 
ME + E2 24h 
7.1 1.71 5.13 1.88 36.65 
7.2 1.79 5.37 1.97 36.69 
3.1 1.46 4.38 1.61 36.76 
3.2 0.77 2.31 0.95 41.13 
3.3 0.85 2.55 1.30 50.98 
  MEDIA       40.44 
ME + E2 48h 
8.1 2.10 6.30 2.89 45.87 
8.2 1.41 4.23 0.855 20.21 
4.1 3.20 9.60 2.67 27.81 
4.2 1.43 4.29 2.14 49.88 
4.3 1.77 5.31 1.6 30.13 
  MEDIA       38.43 
ESTRO 
11.1 1.35 4.05 1.39 34.32 
11.2 1.60 4.80 2.39 49.79 
  MEDIA       42.06 
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Supplementary Figure 1. Flow cytometry gating strategy of peritoneal macrophages. 
Gating strategy for the identification by FACS analysis of neutrophils (CD45+ , CD11c- ,CD19- ,CCR3- , CD11b+ , 
LY6G+ ), eosinophils (CD45+ , CD11c- ,CD19- ,CCR3- , CD11blow, LY6G- ,F4/80low), monocytes (CD45+ , CD11c- 
,CD19- ,CCR3- , CD11b+ , LY6G- ,F4/80+ , LY6C+ ), small peritoneal macrophages (SPM; CD45+ , CD11c- ,CD19- 
,CCR3- , CD11b+ , LY6G- ,F4/80low) and large peritoneal macrophages (LPM; CD45+ , CD11c- , CD19- , CCR3- , 
CD11b+ , LY6G- , F4/80hi). One representative example for peritoneal cells from an unstimulated animal is shown. 
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 Supplementary Figure 2. Flow cytometry analysis of peritoneal macrophages. 
Large and small peritoneal macrophages (LPM and SPM, respectively) were identified by FACS analysis in the 
peritoneal lavage of sham (open bars), ovx (black bars) and ovx+E2 (60 h treatment; grey bars) animals as described 
in Supplementary Figure 1. The percentage of LPM and SPM with respect to the total number of CD45+ cells is 
reported in panel a, the expression level of CD11b, F4/80 and Ly6C are reported as Mean Fluorescence Intensity 
(MFI) in panels b to d, respectively. Results are expressed as the mean ± SEM (n=3). *p < 0.05 versus sham. 
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Supplementary Table 5. M2 genes expression. Ct values and 2-ddCt calculation. 
Peritoneal macrophages were isolated from female mice at the metaestrous phase (ME) of the estrous cycle treated 
with E2 for 3, 24 and 48 h. Females in the estrous phase (E) were also investigated. Real time PCR of two independent 
experiment (A and B) was performed to detect the mRNAs coding for genes related with M2 macrophage 
polarization (Arg1, Ym1,Vegfα). 
Gene expression was normalized on 36B4 expression and data sets for each gene were calculated using the 2-ddCt 
method with respect to the mean value of the control group (ME).  
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Supplementary Table 6. Protein expression of Vegfα (A), IL-10 (B), TNFα (C) in the peritoneal fluid. 
Sham-operated (A1-A13 representative samples), ovariectomized (B1-B12 representative samples), or ovariectomized 
and treated with E2 (C1-C15 representative samples) animals were injected with zymosan (zymo) or 
veh(physiological). Protein concentration of Vegfα (A), IL10 (B) and TNFα (C) was evaluated in peritoneal fluid 
through ELISA assay. 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STIMULUS TIME POINT (?) ID Raw (pg/ml) CF Real (pg/ml) Media (pg/ml) V lavaggio Totale (pg) Media (pg)
Zymo A1 250.46 4.44 56.35 42.53 2 112.71 85.07
Zymo A2 161.8 5.00 32.36 2 64.72
Zymo A3 194.42 5.00 38.88 2 77.77
Physiological A4 145.28 5.13 28.33 28.33 2 56.66 56.66
Zymo A5 221.38 5.00 44.28 39.61 2 88.55 79.22
Zymo A6 187.48 5.00 37.50 2 74.99
Zymo A7 190.05 5.13 37.06 2 74.12
Physiological A8 162.41 5.26 30.86 30.86 2 61.72 61.72
Zymo A9 338.95 5.41 62.71 62.74 2 125.41 125.49
Zymo A10 326.64 5.41 60.43 2 120.86
Zymo A11 361.66 5.56 65.10 2 130.20
Physiological A12 197.5 5.26 37.53 33.32 2 75.05 66.64
Physiological A13 157.39 5.41 29.12 2 58.23
Zymo B1 219.32 5.41 40.57 47.07 2 81.15 94.14
Zymo B2 318.88 5.26 60.59 2 121.17
Zymo B3 210.76 5.26 40.04 2 80.09
Physiological B4 168.96 5.26 32.10 32.10 2 64.20 64.20
Zymo B5 209.77 5.41 38.81 42.37 2 77.61 84.75
Zymo B6 235.1 5.13 45.84 2 91.69
Zymo B7 217.78 5.13 42.47 2 84.93
Physiological B8 151.17 5.13 29.48 29.48 2 58.96 58.96
Zymo B9 257.17 5.13 50.15 51.86 2 100.30 103.72
Zymo B10 127.64 5.00 25.53 2 51.06
Zymo B11 399.51 5.00 79.90 2 159.80
Physiological B12 156.63 5.41 28.98 28.98 2 57.95 57.95
Zymo C1 153.82 5.26 29.23 38.04 2 58.45 76.07
Zymo C2 195.63 5.71 34.24 2 68.47
Zymo C3 266.57 5.26 50.65 2 101.30
Physiological C4 155.81 5.88 26.49 24.12 2 52.98 48.24
Physiological C5 117.58 5.41 21.75 2 43.50
Zymo C6 177.66 5.41 32.87 33.51 2 65.73 67.02
Zymo C7 219.22 6.90 31.79 2 63.57
Zymo C8 188.86 5.26 35.88 2 71.77
Physiological C9 127.54 5.00 25.51 28.30 2 51.02 56.61
Physiological C10 159.48 5.13 31.10 2 62.20
Zymo C11 265.97 5.56 47.87 49.03 2 95.75 98.06
Zymo C12 300.01 5.00 60.00 2 120.00
Zymo C13 150.82 3.85 39.21 2 78.43
Physiological C14 158.31 5.13 30.87 29.19 2 61.74 58.39
Physiological C15 137.58 5.00 27.52 2 55.03
12h
36h
60h
12h
36h
60h
12h
36h
60h
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B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STIMULUS TIME POINT (?) ID Raw (pg/ml) CF Real (pg/ml) Media (pg/ml) V lavaggio Totale (pg) Media (pg)
Zymo A1 11.72 4.44 2.64 7.05 2 5.27 14.10
Zymo A2 30.15 5.00 6.03 2 12.06
Zymo A3 62.39 5.00 12.48 2 24.96
Physiological A4 19.06 5.13 3.72 3.72 2 7.43 7.43
Zymo A5 31.68 5.00 6.34 4.25 2 12.67 8.50
Zymo A6 24.04 5.00 4.81 2 9.62
Zymo A7 8.26 5.13 1.61 2 3.22
Physiological A8 24.61 5.26 4.68 4.68 2 9.35 9.35
Zymo A9 21.58 5.41 3.99 3.66 2 7.98 7.33
Zymo A10 24.03 5.41 4.45 2 8.89
Zymo A11 14.18 5.56 2.55 2 5.10
Physiological A12 19.31 5.26 3.67 2.78 2 7.34 5.56
Physiological A13 10.24 5.41 1.89 2 3.79
Zymo B1 55.99 5.41 10.36 12.05 2 20.72 24.10
Zymo B2 87.19 5.26 16.57 2 33.13
Zymo B3 48.52 5.26 9.22 2 18.44
Physiological B4 7.66 5.26 1.46 1.46 2 2.91 2.91
Zymo B5 36.69 5.41 6.79 5.13 2 13.58 10.25
Zymo B6 10.36 5.13 2.02 2 4.04
Zymo B7 33.71 5.13 6.57 2 13.15
Physiological B8 13.94 5.13 2.72 2.72 2 5.44 5.44
Zymo B9 21.8 5.13 4.25 3.38 2 8.50 6.76
Zymo B10 8.96 5.00 1.79 2 3.58
Zymo B11 20.52 5.00 4.10 2 8.21
Physiological B12 11.26 5.41 2.08 2.08 2 4.17 4.17
Zymo C1 30.07 5.26 5.71 7.89 2 11.43 15.78
Zymo C2 43.71 5.71 7.65 2 15.30
Zymo C3 54.23 5.26 10.30 2 20.61
Physiological C4 13.41 5.88 2.28 2.33 2 4.56 4.66
Physiological C5 12.86 5.41 2.38 2 4.76
Zymo C6 43.05 5.41 7.96 5.59 2 15.93 11.18
Zymo C7 26.04 6.90 3.78 2 7.55
Zymo C8 26.46 5.26 5.03 2 10.05
Physiological C9 19.67 5.00 3.93 3.11 2 7.87 6.23
Physiological C10 11.76 5.13 2.29 2 4.59
Zymo C11 10.86 5.56 1.95 4.41 2 3.91 8.83
Zymo C12 33.59 5.00 6.72 2 13.44
Zymo C13 17.58 3.85 4.57 2 9.14
Physiological C14 13.79 5.13 2.69 2.41 2 5.38 4.82
Physiological C15 10.64 5.00 2.13 2 4.26
12h
36h
60h
12h
36h
60h
12h
36h
60h
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C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STIMULUS TIME POINT (?) ID Raw (pg/ml) CF Real (pg/ml) Media (pg/ml) V lavaggio Totale (pg) Media (pg)
Zymo A1 26.56 4.44 5.98 28.92 2 11.95 57.84
Zymo A2 156.18 5.00 31.24 2 62.47
Zymo A3 247.73 5.00 49.55 2 99.09
Physiological A4 1.29 5.13 0.25 0.25 2 0.50 0.50
Zymo A5 96.18 5.00 19.24 #VALORE! 2 38.47 41.80
Zymo A6 112.84 5.00 22.57 2 45.14
Zymo A7 - 5.13 #VALORE! 2 #VALORE!
Physiological A8 5.94 5.26 1.13 1.13 2 2.26 2.26
Zymo A9 47.79 5.41 8.84 7.46 2 17.68 14.93
Zymo A10 41.69 5.41 7.71 2 15.43
Zymo A11 32.42 5.56 5.84 2 11.67
Physiological A12 10.73 5.26 2.04 2.28 2 4.08 4.56
Physiological A13 13.61 5.41 2.52 2 5.04
Zymo B1 300.86 5.41 55.66 61.97 2 111.32 123.93
Zymo B2 407.46 5.26 77.42 2 154.83
Zymo B3 278.01 5.26 52.82 2 105.64
Physiological B4 17.12 5.26 3.25 3.25 2 6.51 6.51
Zymo B5 146.61 5.41 27.12 22.69 2 54.25 45.39
Zymo B6 113.1 5.13 22.05 2 44.11
Zymo B7 96.94 5.13 18.90 2 37.81
Physiological B8 - 5.13 #VALORE! #VALORE! 2 #VALORE! #VALORE!
Zymo B9 31.25 5.13 6.09 8.40 2 12.19 16.80
Zymo B10 42.01 5.00 8.40 2 16.80
Zymo B11 53.53 5.00 10.71 2 21.41
Physiological B12 - 5.41 #VALORE! #VALORE! 2 #VALORE! #VALORE!
Zymo C1 163.08 5.26 30.99 39.43 2 61.97 78.86
Zymo C2 219 5.71 38.33 2 76.65
Zymo C3 257.82 5.26 48.99 2 97.97
Physiological C4 13.84 5.88 2.35 1.73 2 4.71 3.45
Physiological C5 5.94 5.41 1.10 2 2.20
Zymo C6 33.12 5.41 6.13 11.41 2 12.25 22.82
Zymo C7 113.01 6.90 16.39 2 32.77
Zymo C8 61.63 5.26 11.71 2 23.42
Physiological C9 16.06 5.00 3.21 2.58 2 6.42 5.15
Physiological C10 9.94 5.13 1.94 2 3.88
Zymo C11 8.78 5.56 1.58 11.54 2 3.16 23.08
Zymo C12 146.03 5.00 29.21 2 58.41
Zymo C13 14.74 3.85 3.83 2 7.66
Physiological C14 1.45 5.13 0.28 0.56 2 0.57 1.13
Physiological C15 4.23 5.00 0.85 2 1.69
36h
60h
12h
36h
60h
12h
36h
60h
12h
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Supplementary Table 7. Target gene expression by E2 in isolated macrophages. Ct values and 2-ddCt calculation. 
BMDM (A) or peritoneal macrophages (B) were grown in culture and assayed for gene expression following E2 
administration. (A) BMDM cells were treated with vehicle (veh, open bars) or increasing concentrations of E2 (10 -9, 
10-7 and 10-5 M, filled bars) for 3 h. Real time PCR was used to analyze the mRNA levels coding for Vegfα, Angtpl4 
and Arg1. (C) Comparison of estrogen action in BMDM cells from WT and ERα-KO (ERKO) mice. The mRNA levels 
coding for Vegfα, Angtpl4 and Arg1 were analyzed 24 h after the addition of vehicle (veh, open bars) or 10-7 M E2 
(filled bars). Gene expression was normalized on 36B4 expression and data sets for each gene were calculated using 
the 2-ddCt method with respect to the mean value of the vehicle group. 
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Supplementary Table 8. Expression of E2 target genes in microglia in vivo. Ct values and 2-ddCt calculation. 
Microglia was isolated from female mice at the metaestrous phase (ME) of the estrous cycle treated with E2 for  24 h. 
Real time PCR was performed to detect the mRNAs coding for genes related with M2 polarization (Fizz1, Ym1, 
Vegfα, Gas6) and cell cycle (Ccnb2 and Cdk1). 
Gene expression was normalized on 36B4 expression and data sets for each gene were calculated using the 2-ddCt 
method with respect to the mean value of the control group (ME). 
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 Supplementary Table 9 . Cell cycle genes expression following  IL-4 treatment in peritoneal macrophages and 
brain microglia  in vivo. Ct values and 2-ddCt calculation. 
Animals were treated for 24h with IL-4 or veh through icv injection for brain analysis (A; some representative 
samples) or i.p. for peritoneal macrophages analysis (B). Real time PCR was performed to detect the mRNAs coding 
for genes related with cell cycle(Cdk1, Ccnb2 and Ki67) and M2 polarization (Arg1) in brain (A) and peritoneal 
macrophages (B). Gene expression was normalized on 36B4 expression and data sets for each gene were calculated 
using the 2-ddCt method with respect to the mean value of the vehicle group (ME). 
A. 
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Supplementary Table 10. Oligonucleotides used in real time PCR assays. 
 
Gene Forward sequence Reverse sequence 
Vegfα 5'-AGCAGAAGTCCCATGAAGTGA-3' 5'-ATGTCCACCAGGGTCTCAAT-3' 
Arg1 5'-GAATCTGCATGGGCAACCT-3' 5'-ACACGATGTCTTTGGCAGATAT-3' 
Ym1 5′-GAAGGAGCCACTGAGGTCTG-3′ 5′-GAGCCACTGAGCC TTCAAC-3′ 
Tgm2 5'-GGCCACTTCATCCTGCTCTA-3' 5'-TCCAAGGCACACTCTTGATG-3’ 
Il10 5'-GGTTGCCAAGCCTTATCGGA-3' 5'-ACCTGCTCCACTGCCTTGCT-3’ 
Fizz1 5'-GGAACTTCTTGCCAATCCAGC-3' 5'-AAGCCACAAGCACACCCAGT-3' 
Gas6 5'-CTTAGCCAGGATGACCGGAG-3' 5'-AGCACAGTGTGAGAAGACTCG-3' 
Tnfα 5'-CCTATGTCTCAGCCTCTTCTC-3' 5'-CTCTTGCTTATCCCCTCTTCC-3' 
CcnB2 5'-CCGACGGTGTCCAGTGATTT-3' 5'-CTGAGGTTTCTTCGCCACCT-3' 
Cdk1 5'-ACACGAGGTAGTGACGCTGT-3' 5'-TCAATCTCTGAGTCGCCGTG-3' 
Ube2c 5’-ATAGCCCTTTGAACACACACG-3’ 5’-TGGAGACCTGCTTTGAATAGG-3’ 
Ki67 5'-AGAGCTAACTTGCGCTGACT-3' 5'-TCAATACTCCTTCCAAACAGGCA-3' 
Angptl4 5'-ATGACTTCAGATGGAGGCTGG-3' 5'-AATTGGCTTCCTCGGTTCCC-3' 
36B4 5′-GGCGACCTGGAAGTCCAACT-3 5′-CCATCAGCACCACGGCCTTC-3′ 
 
 
 
